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Abstract 
Major Depressive Disorder (MDD) is one of the most common mental health disorders in the world 
and yet, current treatments for MDD are very ineffective. There is an urgent need to find novel 
treatments with increased efficacy and reduced side effects. Increased levels of adrenomedullin 
(ADM), a short vasodilator peptide, are found in the blood of MDD patients. There are currently no 
known small molecular inhibitors of the two ADM receptors, ADM1 and ADM2. We procured seven 
small molecular compounds capable of antagonising the ADM2 receptor, from the European Lead 
Factory. These compounds were selected by high throughput screening.  The ability of the 
compounds to block different pathways involved in ADM signalling was assessed. The most 
canonical pathway for ADM signalling is the activation of adenylate cyclase to increase intracellular 
cAMP. Measurements of intracellular ATP concentration revealed promising results for two of the 
compounds, TC14 and TC02. SKNSH cells pre-treated with 100 µM of these antagonist compounds 
and then treated with 1 µM of ADM peptide agonist had reduced cAMP, compared with cells treated 
with 1 µM of ADM agonist only. Pre-treatment with TC14 and TC02 resulted in intracellular cAMP 
concentrations of 0.7 nM and 5.3 nM, respectively, compared to a cAMP concentration of 31.3 nM in 
cells treated only with ADM agonist. We suggest that these compounds can be used in further 
research into the role of ADM in MDD. The hypothesis that some of the effects mediated by ADM, in 
health and disease, are dependent on the phosphorylation and inhibition of the transcription factor 
FoxO3a, via PI3K/Akt signalling, was also investigated. 
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1. Introduction 
 
1.1. Major Depressive Disorder 
 
Major Depressive Disorder (MDD), also known as unipolar depression or major depression, is 
characterised as a negative mood (dysphoria) that lasts for more than two weeks at a time. The 
diagnosis of major depression may also require the presence of other physical or mental symptoms, 
including anhedonia (loss of pleasure in once pleasurable activities), persistent feelings of guilt and 
worthlessness, suicidal thoughts, weight loss (or in some cases weight gain), fatigue, inability to 
concentrate, and psychomotor retardation (Goodyer, 2003). It is one of the most common mental 
disorders in the world. In 2011, there was an estimated prevalence of 6.9 % of people in Europe 
(Wittchen et al., 2011), and this percentage is predicted to rise. This constitutes a large economic 
burden and current treatments for MDD have been shown to be ineffective and come with 
unpleasant side effects including nausea, headaches and sexual dysfunction (Ferguson, 2001). 
NICE guidelines suggest that non-pharmacological treatments be attempted first, such as physical 
exercise and changes to the diet, as well as emotional support from friends and family. Anti-
depressants are considered to be of low effectiveness relative to the risk they pose, especially in 
suicidal patients who may attempt to over-dose (NICE guideline, 2018).  
The major classes of antidepressants currently used to treat MDD, along with other mood disorders, 
include tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs) and 
neurotransmitter reuptake inhibitors, such as selective serotonin reuptake inhibitors (SSRIs) 
(Herrman et al., 2009). These treatments are based on the monoamine hypothesis of major 
depression, the theory that depression is caused by the depletion of monoamine neurotransmitters 
in the central nervous system (Delgado, 2000). SSRIs are the first choice of anti-depressant, 
according the BNF guidelines, due to the class being the most tolerated and safest drug when taken 
in over-dose. It is only when a patient fails to respond to SSRIs that other drugs, such as mirtazapine 
– an α2-adrenorecptor antagonist, leading to increased noradrenergic and serotonergic 
neurotransmission – are prescribed (NICE, 2019). It is now believed that synaptic plasticity may be 
important in the pathology of depression in specific regions of the brain, including the hippocampus 
(Marsden, 2013). The number of patients who are non-responsive to anti-depressants is high, with 
varying reports on the actual percentage of non-responders to first line treatment. In 2004 a study 
investigating the treatment of MDD with SSRIs, found that 46% of patients did not respond (Corey-
Lisle et al., 2004).  As a result, there is a pressing need for new and more effective treatments for 
MDD to be developed. 
Inflammation is thought to be of key importance in the pathology of depression. Increased 
childhood levels of inflammatory cytokines such as interleukin-6 (IL-6) and complement reactive 
protein (CRP), in children, are linked to an increased risk of developing depression. Cytokines are 
thought to promote dysregulation of the hypothalamic-pituitary adrenal (HPA) axis, also linked to 
depression (Kiecolt-Glaser et al., 2015). Treatments aimed at reducing inflammation and 
dysregulation of the HPA axis, in combination with SSRIs and other anti-depressants, may be the way 
forward for a more effective treatment for major depression.  
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1.1.1. Major Depressive Disorder and Adrenomedullin 
 
Patients with MDD were found to have elevated levels of adrenomedullin (ADM) and nitric oxide 
(NO) compared to healthy controls (Akpinar et al., 2013). The reason for this has yet to be 
elucidated, however Akpinar et al. suggested the neuroprotective role of ADM against inflammation 
and oxidative stress as a possibility. On the other hand, the elevated levels of ADM may be 
contributing to the pathology of MDD, potentially exacerbating the condition via the role of ADM in 
the regulation of the HPA axis. 
ADM is thought to be involved in the regulation of the HPA axis, which is involved in the response to 
different types of stress. ADM and its receptor components, CLR and RAMP2, are expressed in the 
hypothalamus, pituitary gland and adrenal gland. ADM knockout in mice resulted in anxiety and 
other behavioural changes in response to stress. ADM administered to the pituitary gland, also led to 
decreased adrenocorticotropic hormone (ACTH) secretion. ACTH is a hormone secreted in response 
to stress conditions. This suggests that ADM has a role in regulating response to stress via the HPA 
axis (García-Sanmartín et al., 2013). Hyperactivity of the HPA axis, due to reduced response to 
negative feedback mechanisms, has been linked to MDD and is thought to be involved in the 
predisposition of individuals to developing the disorder (Pariante & Lightman, 2008). Increased ADM 
levels in MDD patients may be in response to a hyperactive HPA axis. 
There is evidence that ADM may play an important role in the response of individuals to anti-
depressant treatment. A single-nucleotide polymorphism (SNP), resulting in altered ADM expression, 
affects the probability of MDD patients responding to the anti-depressant, paroxetine. Patients 
expressing the allele resulting in increased expression of the ADM were more likely to respond to 
treatment with paroxetine (Glubb et al., 2010). This further supports the role of ADM in MDD. 
Response to anti-depressant treatment has also been linked to inflammation and oxidative stress. 
Patients with higher levels of inflammation markers, tumour necrosis factor alpha (TNF-α) and IL-6, 
and oxidative stress markers, 8-OH 2-deoxyguanosine (8-OHdG) and F2-isoprostanes, were less likely 
to respond to treatment with SSRIs (Lindqvist et al., 2017). Therefore, the antioxidant properties of 
ADM (Hu et al., 2017) may improve MDD patient response to anti-depressants. Therefore, although 
it is clear that ADM is important in MDD, it is unclear whether increased levels of ADM are beneficial 
or detrimental.  
 
1.2. Adrenomedullin 
 
1.2.1. Physiology and Pathophysiology 
 
ADM is a vasodilator, peptide hormone and was first discovered in 1993 by Kitamura et al., from 
pheochromocytoma tissue extracts. Pheochromocytoma is a tumour of the adrenal medulla. ADM 
was so named as it was isolated from both healthy and pheochromocytoma tissue of the adrenal 
medulla (Kitamura et al., 1993). In addition to the adrenal medulla, ADM is also synthesised in 
almost all mammalian tissue types including endothelial cells, vascular smooth muscle cells and the 
central nervous system.  
12 
 
Since its discovery, ADM has been implicated in a range of different diseases including cancer, 
cardiovascular disease and neurological disorders (Ferrero et al., 2018a; Nishikimi et al., 2013; Qiao 
et al., 2017). Increased levels of ADM have been linked to decreased tubulin acetylation in 
Alzheimer’s disease. This suggests ADM could have a role in cytoskeleton destabilisation and 
potentially neuronal plasticity (Ferrero et al., 2018b), which may be relevant in the role of ADM in 
MDD. 
 
1.2.1.1. Complement factor H 
 
Complement factor H (CFH) is a peptide involved in the alternative pathway of the complement 
system. It regulates this aspect of the immune system, helping to protect the body’s healthy cells. In 
the blood plasma, ADM is bound by CFH which, as a result, is also known as adrenomedullin binding 
protein 1 (AMBP1) (Pio et al., 2001).  
 
 
1.2.2. Structure 
 
ADM is a member of the calcitonin peptide family, which also includes calcitonin, calcitonin gene-
related peptide (CGRP), amylin and the most recently discovered, adrenomedullin 2 (ADM2), also 
known as intermedin. The peptides in this family share a similar simple secondary structure. 
However, ADM has an extended N-terminal region with 15 amino acids before the six amino acid 
ring structure, compared to just one amino acid for CGRP.  
All of the peptides have an N-terminal ring structure, formed by a disulphide bond between two 
cysteine residues, and a C-terminal amidated aromatic residue. In ADM, the disulphide bond is 
formed between cysteine residues 16 and 21, and the amidated C-terminal residue is tyrosine. 
Receptor binding experiments have shown that amidation of the C-terminal residue is essential for 
receptor binding and the N-terminal ring structure is essential for activation of the receptor 
(Robinson et al., 2009). Figure 1.1 shows the primary structure of the mature ADM peptide and 
highlights the disulphide bond forming the N-terminal ring, as well as the amidated C-terminal 
tyrosine.  
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Figure 1.1. The structure of the mature ADM peptide 
The structure reveals the six-amino acid ring structure, formed by a disulphide bond between Cys 16 and 21, 
and the amidated c-terminal Tyr 52. Cys 16 and 21 are shown in yellow, and Tyr 52 is shown in blue.  
Although the members of the calcitonin peptide family share the essential structural features 
required for receptor binding and activation, the peptides share little of their amino acid sequences. 
Figure 1.2 shows the sequence alignment of human ADM, ADM-2 and CGRP. The residues 
highlighted in green are the only identical amino acids shared across all three of the peptides. As the 
names suggest ADM shares the highest sequence identity with, and is therefore likely to be most 
closely related to, ADM2 at 34 % identity, whereas between ADM and CGRP sequence identity is just 
19 %.  
 
                          10        20        30        40        50          
                 ....|....|....|....|....|....|....|....|....|....|... 
ADMlcl|Query_10001  YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTD-KDKDNVAPRSKISPQGY  
AM2lcl|Query_10002  ------TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY  
CGRlcl|Query_10003  --------------ACDTATCVTHRLAGLLSRSGG-VVKNNFVPTNVGSKAF-  
 
 
Figure 1.2. ADM vs ADM2 vs CGRP human peptide sequence alignment 
The alignment was made using the U.S. National Library of Medicine’s Constraint-based Multiple Alignment 
Tool (COBALT) – www.ncbi.nlm.nih.gov/tools/cobalt/re_cobalt.cgi. Top line = Adrenomedullin, middle line = 
Adrenomedullin 2 and bottom line = Calcitonin Gene-Related Peptide. Green highlighted residues = residue 
identity between peptide sequences. Grey highlighted residues = residues with similar properties.  
 
1.2.3. ADM gene and peptide processing 
 
The gene encoding ADM was first discovered and sequenced in 1994 (Ishimitsu et al., 1994). ADM is 
located on chromosome 11 in humans, and is made up of four exons and three introns. The gene 
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actually codes for a 185 amino acid precursor protein known as preproadrenomedullin (preproADM) 
(Beltowski & Jamroz, 2004). The start codon for preproADM is located in exon 2 and the sequence 
coding for the mature ADM peptide is located entirely in exon 4 (Ishimitsu et al., 1994).  
Proteolytic cleavage of preproADM yields proadrenomedullin N-terminal 20 peptide (PAMP) and 
ADM, both are biologically active. The precursor peptide is initially cleavage at the site between 
Thr21 and Ala22, removing the N-terminal signal sequence and leaving a 164 amino acid propeptide, 
proadrenomedullin (proADM)(Dipette & Supowit, 2008). ProADM is cleaved at the site Lys43-Arg44, 
producing the PAMP peptide, which is C-terminal amidated to form the active peptide. Mature ADM 
is formed from residues 95-146 of the preproADM precursor peptide (Beltowski & Jamroz, 2004; 
Dipette & Supowit, 2008). The glycine residue 147 is included in the immature ADM peptide and is 
processed by the peptidylglycine alpha-amidating monooxygenase (PAM) enzyme, forming the 
amidated C-terminal tyrosine of the mature ADM peptide. Figure 1.3. shows which amino acids of 
the precursor peptide form the biologically active peptides, PAMP and ADM.  
 
 
Figure 1.3. The precursor peptide of ADM, preproADM, encoded by ADM 
The N-terminal signal sequence is cleaved and amino acids 95-147 produce the immature form of 
Adrenomedullin (iADM), with amino acids 22-41 forming the other biologically active peptide coded for by 
ADM, PAMP. Immature ADM is further processed by the enzyme peptidylglycine alpha-amidating 
monooxygenase (PAM), forming the amidated Tyr from the C-terminal glycine residue.  
 
1.2.4. Receptors 
 
The ADM receptors are formed from two proteins, the calcitonin receptor-like receptor (CLR) and a 
receptor activity modifying protein (RAMP), either RAMP 2 or RAMP 3. The CLR is a G-protein 
coupled receptor (GPCR), belonging to the class B family of GPCRs and its structure is similar to the 
other GPCRs in this class. It comprises of a seven-transmembrane domain (7 TMD) and a large N-
terminal extracellular domain (ECD) (de Graaf et al., 2017). Peptide ligands bind to class B GPCRs in a 
manner known as the ‘two domain model’ where the C-terminus of the peptide binds to the ECD of 
the receptor and the N-terminus binds to the TMD, activating the receptor (Parthier et al, 2009). This 
model explains the importance of the C-terminal amidated tyrosine residue for the binding of the 
ADM peptide to the ADM receptors, and the requirement of the N-terminal ring structure, formed 
by the disulphide bond, for ADM-mediated activity.  
There are three known RAMPs, namely RAMP 1, 2 and 3. Human RAMPs 1 and 3 have a precursor 
protein length of 148 amino acids whereas RAMP 2 is larger with a precursor length of 180 amino 
acids. They share little sequence identity but have a similar basic structure consisting of a large 
extracellular domain, single transmembrane domain and a short cytoplasmic domain (Sexton et al., 
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2001). RAMPs have two functional roles in the ADM receptors. One role involves facilitating the 
trafficking of the CLR from the endoplasmic reticulum (ER), through the Golgi body, to the cell 
surface membrane (McLatchie et al., 1998). A reason for this might be that RAMP binding to CLR 
stabilises the structure of the receptor, allowing proper folding of the protein and therefore allowing 
CLR to exit the ER. Without the expression of a RAMP, the CLR is not glycosylated at the N-terminus, 
a requirement for receptor processing, and remains in the ER of the cell (Bolander Jr, 2004; 
Dickenson et al., 2013). The transport pathway of CLR to the cell surface is shown in Figure 1.4. 
RAMPs also determine the pharmacology of the receptor. CLR/RAMP2 forms the ADM1 receptor and 
CLR/RAMP3 forms the ADM2 receptor, both are specific for ADM, however CLR/RAMP1 forms a 
receptor specific to CGRP. Figure 1.5 shows the basic structure of the ADM receptors. It is worth 
noting that there is some cross specificity for ADM and CGRP between these receptors, with ADM2 
and CGRP receptors activated by both ADM and CGRP, yet ADM1 is highly specific for ADM (Hay et 
al., 2004).  The selectivity of the receptors is determined by the RAMP, via allosteric interactions 
with the CLR component of the receptor and direct interactions with residues of the peptide ligand. 
An example of an important interaction between a RAMP and the peptide ligand is the hydrogen 
bonding of RAMP2 residue E101 with the ADM terminal residue Y52, discovered via X-
crystallography structure determination of the ECD domain of RAMP2:CLR (Booe et al., 2015; Booe 
et al., 2018).  
 
Figure 1.4. Representation of the pathway of the receptor from the ER to the cell surface membrane 
The RAMP is essential for the movement of the CLR receptor component to the cell surface. The reason for this 
may be that the RAMP aids the proper folding of the CLR, as it is vital that a protein is properly folded before it 
can exit the ER.  
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Figure 1.5. Representation of the ADM receptor 
The CLR component of the receptor has seven transmembrane domains and the accompanying RAMP has a 
single transmembrane domain. 
 
1.2.5. Current understanding of signalling pathways  
 
The majority of the literature on ADM-mediated signalling is focussed on cAMP production via 
adenylate cyclase activation and initially this was thought to be the only pathway activated upon 
ADM binding to its specific receptors (Hay et al., 2018; Yoshimoto & Hirata, 2005). This is not 
surprising as the peptide was discovered due to its ability to elevate cAMP levels in platelets 
(Kitamura et al., 1993). However, it has since been elucidated that multiple other signalling pathways 
are involved in mediating the physiological effects of ADM including the NO/cGMP, PI3K/Akt and 
ERK/MAPK pathways (Yoshimoto & Hirata, 2005).  
Studies have shown that certain physiological effects of ADM, including inhibition of apoptosis and 
vasodilation, are mediated by the activation of the NO/cGMP pathway (Matteo & May, 2003; Sata et 
al., 2000). The activation of the ADM receptor stimulates neuronal nitric oxide synthase (nNOS) to 
produce nitric oxide (NO) which, in turn, stimulates guanylate cyclase (GC) to produce cGMP. A 
summary of the canonical ADM signalling pathway and how this leads to NO and cGMP production is 
shown in Figure 1.6. 
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Figure 1.6. Canonical signalling pathway of ADM and mechanism for ADM-mediated NO production adapted from 
Figure 7 of (Yen et al., 2011) 
ADM binding to the receptor activates the G protein bound to the CLR component of the receptor. The Gαs sub 
unit of the G protein activates adenylate cyclase, stimulating the production of cAMP. Neuronal NOS is 
activated via PKA, stimulating NO production, which activates guanylate cyclase to produce cGMP.  
 
The main component of the ADM receptors and the CGRP receptor is the CLR, which is a class B 
GPCR. The signalling pathway activated by a GPCR is determined by the G-protein. The activation of 
adenylate cyclase (AC) is mediated by the coupling of the ADM receptor to the Gαs protein. This 
leads to the inhibition of cAMP production by AC. As ADM stimulation mainly leads to the 
production of cAMP, it is thought that the ADM receptor is primarily coupled to the Gαs protein.  
The CGRP receptor is also suggested to interact with the Gαs protein as well as the Gαq/11 protein and 
also mediate G-protein independent signalling, via β-arrestin (Walker et al., 2016). Studies 
investigating ADM and CGRP receptor-binding activity have also suggested that some of the 
physiological effects of ADM may be mediated via the CGRP receptor. Therefore pathways activated 
by these G-proteins may also be relevant to ADM activity (Yoshimoto & Hirata, 2005). The ADM 
receptors could also activate these pathways. 
Beta-arrestins are adaptor proteins that are involved in GPCR signalling desensitization. The 
conformational change caused by receptor-ligand binding results in recognition by GPCR kinases 
(GRKs). GRK 4 and 5 recognise the ADM receptors (Kuwasako et al., 2016), which phosphorylate the 
C-terminal of the receptor specific sites. These sites are recognised by β-arrestins and the receptor is 
internalised, preventing further activation of G-protein-mediated signalling (Kovacs et al., 2009).  
Initially β-arrestins were thought to only be involved in receptor desensitisation, however the 
adaptor proteins are now associated with the activation of signalling pathways including the 
PI3K/Akt pathway. The mechanisms by which β-arrestins interact with these pathways are complex 
and can inhibit or activate the signalling molecules depending on the proteins recruited by the β-
arrestin (DeFea, 2008). β-arrestin 1 was found to activate PI3K, leading to the subsequent 
phosphorylation and activation of Akt in insulin growth factor 1 (IGF-1) signalling (Povsic et al., 
ADM1/2 
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2003). ADM has been found to activate the PI3K/Akt pathway to inhibit apoptosis, as with IGF-1 
signalling, and due to the association with ADM/CGRP receptors and β-arrestin mediated signalling, 
potentially ADM could activate PI3K/Akt signalling via this mechanism (Povsic et al., 2003).   
PI3K can also be activated by the Gβγ complex, a dimeric complex which binds to the Gα subunit of 
the G protein complex when the GPCR is inactive, releasing the subunit upon ligand binding and 
GPCR activation (Schwindinger & Robishaw, 2001; Stephens et al., 1994). Therefore, there is also a 
possibility that ADM could activate the PI3K/Akt pathway via this mechanism.  
 
1.2.6. CGRP-receptor component protein (RCP) 
 
Another component of the ADM receptors, suggested to be important for signal transduction, is the 
CGRP-receptor component protein (RCP). In humans CGRP-RCP is 148 amino acids in length. The 
protein is highly conserved across species with the human, mouse and rat forms of the protein 
sharing almost 90 % sequence identity.  
RCP has been found to interact directly with the CLR component of the ADM and CGRP receptors 
and enhance the ADM/CGRP-mediated signal. However, RCP does not affect the affinity of the ligand 
for the receptor (Evans et al., 2000). RCP is expressed in most immortalised cell lines, yet in vivo 
expression is more specific to cell subsets (Dickerson, 2013). RCP expression localises to CGRP-
responsive sites (Rosenblatt et al., 2000). 
There is much evidence that RCP is important in enhancing ADM and CGRP receptor activity when 
Gαs is coupled to the receptor leading to an increase in intracellular cAMP levels. However, it is yet 
to be made clear whether RCP is important in other signalling pathways mediated by ADM. It may be 
that RCP is involved in signalling biased, resulting in the observed favouring of the cAMP signal 
pathway. In vivo, cells, which do not express RCP, may mediate the physiological effects of ADM via 
alternative pathways, such as the PI3K/Akt pathway.  
 
1.2.7. Peptide antagonists and Adrenomedullin Modulators 
 
All of the current ADM antagonists are peptide-based. These are truncated versions of ADM without 
the N-terminal ring structure. One such fragment is ADM22-52, which is the only commercially 
available antagonist. However, ADM22-52 has low affinity for the receptors. Robinson et al. developed 
other peptide antagonists of the CGRP and ADM receptors, by experimenting with different peptide 
truncations and peptide chimeras of ADM and αCGRP. They demonstrated regions of the peptides 
required for determining the receptor specificity and also residues that may be involved in 
interactions with the RAMP components of the receptor, however were unable to develop an 
antagonist significantly more effective than the existing ADM22-52 (Robinson et al., 2009).  
Despite the availability and effectiveness of ADM22-52 at inhibiting the ADM receptors, the 
development of a small molecular antagonist is desirable. This is because, peptide-based 
therapeutics are often unstable due to the oral unavailability and short plasma half-life of peptides. 
This is particularly relevant in regards to ADM which has a half-life of only around 22 minutes 
(Meeran et al., 1997). A small molecular antagonist would allow the progression of research on the 
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different signalling pathways the receptors may activate and would have the potential to be 
developed into a clinical treatment for the multiple ADM-associated diseases. 
Martínez et al. screened small molecules that were able to modulate the effectiveness of ADM, 
positively or negatively (Martińez et al., 2004). The compounds were initially screened for their 
ability to block the interaction of the ADM peptide and an anti-ADM, neutralizing monoclonal 
antibody. The compounds were then evaluated on the effect they had on cAMP levels when 
administered to cells also treated with ADM. Some of the compounds were able to reduce the level 
of cAMP, compared to ADM alone, whereas others increased the level of cAMP (Martińez et al., 
2004). Although these small molecules appear to disrupt or enhance ADM signalling, and 
experiments using these small molecules suggest that they can affect ADM-associated effects 
related to cancer (Ochoa-Callejero et al., 2017; Siclari et al., 2014), the mechanism of how they 
achieve these effects is unclear. Martínez et al. suggest that the small molecular modulators act by 
binding to ADM itself (Martińez et al., 2004), rather than the receptors, and therefore may be 
effective through causing a conformational change of ADM rather than binding to its receptors. 
 
1.3. FoxO3a 
 
ADM signalling is not only mediated via adenylate cyclase activation and cAMP, but also via PI3K and 
Akt activation (Miyashita et al., 2003). Phosphorylation of FoxO3a by Akt blocks the transcriptional 
activity of the protein and reduced levels of FoxO3a has been shown to have more long-term 
neuroprotective effects (Sun et al., 2018). Therefore, perhaps the neuroprotective effects of ADM 
are mediated by the Akt-phosphorylation and inhibition of FoxO3a.  
Forkhead box-containing (FoxO) proteins are a subgroup of transcription factors. The nematode 
homolog is known as Daf-16 and is involved in determining lifespan (Kenyon et al., 1993). There are 
also four mammalian FoxOs: FoxO1, FoxO3 (FoxO3a), FoxO4 and FoxO6, and a fruit fly (Drosophila 
melanogaster) homolog dFoxO (McLaughlin & Broihier, 2018).  
The nuclear localisation of the forkhead-box transcription factor FoxO3a results in cell apoptosis. 
Treatment of PC12 cells with corticosterone mimics the hyperactivity of the HPA axis, which has 
been linked to mood disorders such as anxiety, depression and schizophrenia (Bradley & Dinan, 
2010; Varghese & Brown, 2001), and leads to cell apoptosis. Clozapine is an antipsychotic drug used 
to treat refractory schizophrenic patients and was found to inhibit corticosterone-induced apoptosis, 
via the PI3K/Akt/FoxO3a pathway. Treatment of cells with clozapine increases the phosphorylation 
of Akt and FoxO3a, which inactivates the transcription factor and prevents its translocation into the 
nucleus (Zeng et al., 2017). This suggests activation of PI3K/Akt, and therefore inactivation of 
FoxO3a, could be neuroprotective. ADM has been shown to prevent apoptosis in cardiomyocytes via 
activation of the PI3K/Akt pathway (Okumura et al., 2004). Perhaps this mechanism of action in 
cardiomyocytes is dependent on FoxO3a. Our hypothesis is that ADM may be able to inhibit FoxO3a 
transcriptional activity, via PI3K/Akt –dependent phosphorylation. This may occur by ADM binding to 
its receptor and activating the G protein bound to the receptor. The G protein then separates into 
the Gαs component, which activates adenylate cyclase, and the Gβγ component, which is thought to 
activate PI3K (Merlot & Firtel, 2003). Akt (also known as protein kinase B) is then activated via the 
PI3K-dependent phosphorylation of PIP2 to form PIP3, which activates PDK1 and, in turn, Akt. Akt 
phosphorylates FoxO3a at the sites Thr 32, Ser 253 and Ser 315 (Tzivion et al., 2011). FoxO3a in its 
phosphorylated form is unable to translocate across the nuclear membrane and, as a result, is no 
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longer transcriptionally active. A summary of the proposed pathway of ADM-mediated inhibition of 
FoxO3a transcriptional activity is shown in Figure 1.7.   
 
Figure 1.7. The possible mechanism by which ADM could mediate the inhibition of the Foxo3a transcription factor 
 
Analysis of RNA polymerase II activity in coding regions, rather measuring mRNA levels, has revealed 
FOXO3 transcriptionally regulates a variety of genes. These include, but are not limited to, genes 
involved in the PI3K/Akt signalling pathway (IGF1R, IRS2 and RICTOR) and in the cell-cycle (CCNB1 
and CCNG2) (Eijkelenboom et al., 2013). IGF1R and IRS2 code for insulin-like growth factor receptor 
1 and insulin receptor substrate 2, respectively, and have been linked to longevity via the inhibition 
of FoxO3a via the PI3K/Akt pathway. RICTOR codes for a peptide which is part of the mTOR complex 
2, involved in Akt-dependent FOXO phosphorylation. IGF1R, IRS2 and RICTOR are all down regulated 
by FoxO3a, suggesting a mechanism of auto negative regulatory feedback (Eijkelenboom et al., 
2013). CCNB1 and CCNG2 code for cyclins B1 and G2, respectively. These cyclins are involved in the 
regulation of the cell-cycle. Cyclin B1 promotes the cell to leave the G2 phase of the cell cycle and 
enter mitosis, and so promotes cell-cycle progression and cell proliferation. Cyclin G2 is an atypical 
cyclin that inhibits cell-cycle progression. FoxO3a was found to down regulate CCNB1 and up 
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regulate CCNG2 (Eijkelenboom et al., 2013). This suggests FoxO3a prevents cell proliferation. 
Therefore, if ADM inhibits FoxO3a, this could partially explain increased levels of ADM in cancer 
patients (Larráyoz et al., 2014). 
 
1.4. Project Aims and Objectives 
 
There are many individuals who do not respond to available antidepressant treatments, and those 
who do respond still have to face the possibility of unpleasant side effects. Therefore, there is a 
demand for a new, more effective therapeutic to be developed, to treat or increase the 
effectiveness of current treatments for MDD, and reduce side effects. ADM has been shown to be 
increased in patients with MDD (Akpinar et al., 2013; Mahajan et al., 2017) and as a result is a 
potential target for the development of a therapeutic to treat the disorder. However, currently, 
there are no known small molecular ADM receptor antagonists available.  
Seven small molecules have been identified via high-throughput screening of the European Lead 
Factory’s (ELF) compound library. These molecules are possible antagonists of the ADM2 receptor. 
The aim of this project was to assess the ability of the compounds to antagonise ADM activity in cell 
lines where the ADM receptors are naturally expressed, whereas in the ELF assays the receptors 
were stably transfected into the cell line, and to ensure the ELF results could be recapitulated. 
Although ELF have only selected for compounds against the ADM2 receptor, we also accessed the 
ability of the compounds to antagonise the ADM1 receptor. This is because there is known cross-
specificity for ligands of the two receptors (Weston et al., 2016) and so the antagonists may bind to 
and be active against both of the receptors.  
The ELF initial testing only assessed the ability of the compounds to inhibit ADM-mediated cAMP 
level increase; therefore, another aim of the project was to investigate whether the compounds 
could affect other signalling pathways induced by ADM. The pathway chosen for this was the 
PI3K/Akt signalling pathway, specifically the effect of activated Akt-mediated phosphorylation of 
FoxO3a.  
The hypothesis of the project is that the small molecule ADM receptor antagonists will be able to 
block ADM-mediated signalling via cAMP and via PI3K/Akt dependent phosphorylation of FoxO3a. 
In summary, the main objectives of this project were as follows: 
 Identify suitable cell lines to investigate the effects of the ADM receptor antagonists 
 Use pathways known to be involved in ADM signalling (cAMP) to verify the ability of the 
antagonists to inhibit ADM-mediated activity 
 Investigate other pathways that may be involved in ADM activity (PI3K/Akt dependent 
FoxO3a phosphorylation) and the effects of the antagonist compounds on these pathways 
2. Materials and Methods 
 
2.1. Cell Culture 
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During culture, cells were incubated in standard conditions of 21 % oxygen, 5 % carbon dioxide and 
at a temperature of 37 °C, unless otherwise stated. The cell lines THP-1, SH SY5Y, 1321N1 and SKNSH 
were purchased from the European Collection of Authenticated Cell Cultures (ECACC). Human 
umbilical vein endothelial cells (HUVECs) were supplied by ATCC.  
 
2.1.1. THP-1 Cells 
 
THP-1 cells are a monocytic cell line derived from a patient with acute monocytic leukaemia. As this 
cell line is haematopoietic, the cells grow in suspension. As a result, the passaging of the cells 
involved removing half of the cells from the flask and topping up the volume in the flask with fresh 
media. Media requirements for the THP-1 cells were as follows: RPMI 1640 Medium (SigmaAldrich, 
Missouri, USA) + 10% FBS+ 2mM L-glutamine. 
 
2.1.2. SH SY5Y Cells 
 
SH SY5Y cells are a neuroblastoma cell line, which are a subclone of the SK N SH cell line. SK N SH 
cells were originally isolated from the bone marrow of a four-year old female patient with 
neuroblastoma. The cell line is adherent and forms a monolayer in the cell culture flask. To passage 
the cells, the medium was removed and the cells were washed with PBS. The PBS was removed and 
1x trypsin was added to the layer of cells, at a ratio of approximately 40-100 µL per 1 cm2 of surface 
area. The cells were incubated for 4 minutes at 37 °C. Fresh medium was added to the cells at twice 
the volume of trypsin added. The cells were vigorously agitated to ensure all cells were detached 
from the flask and to create a single cell solution. The cells were centrifuged at 500 x g for 5 mins, to 
remove the trypsin. The supernatant was removed and the cell pellet was resuspended in fresh 
medium. Cells were split 1:8 with medium and placed back in incubation at 37 °C, in a humid 
environment. Cells were allowed to reach 70-80 % confluency before passaging, with a maximum 
passage number of 20. The medium requirements for SH SY5Y cells were as follows: Ham’s 
F12:EMEM (Gibco, Dublin, Ireland) (EBSS) (1:1) + 2 mM L-glutamine + 10 % Foetal Bovine Serum 
(FBS). 
 
2.1.3. Astrocytes – 1321N1 cell line 
 
The astrocytes grown for this project were human and of the 1321N1 cell line. As the name suggests, 
the astrocytes were derived from human astrocytoma tissue. The cells have a short doubling time 
and required passaging every couple of days. They are an adherent cell line and are passaged in the 
same way as SH SY5Y cells. The media requirements for these astrocytes were DMEM (SigmaAldrich, 
Missouri, USA) + 2 mM L-glutamine + 10 % FBS. 
 
2.1.4. Human Umbilical Vein Endothelial Cells (HUVECs) 
 
HUVECs are primary cells isolated from the vein of human umbilical cords. HUVECs may be derived 
from multiple donors and also from donors of different ethnic backgrounds. Therefore, the cells may 
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differ on a genetic and molecular level, and so it is important to consider these factors when using 
the cells in experiments (Nor Suhaila & Safuan, 2017). The cells were passaged and maintained in the 
same way as SH SY5Y cells in section 2.1.2. HUVECs appeared to grow at slower rate than that of SH 
SY5Y cells however and so required passaging less frequently. In addition, HUVECs can only reach a 
passage number of between 5 and 10 before becoming non-viable. The cells were grown in 
Endothelial Cell Growth Medium (Cell Applications inc., California, USA.) which was supplied already 
containing serum and growth factors.  
 
2.1.5. SK N SH 
 
As mentioned in section 2.1.2., SK N SH cells were originally derived from metastatic neuroblastoma 
tissue in the bone marrow of a four-year old female. SK N SH is a neuronal cell line and contains a 
high level of dopamine-β-hydroxylase, usually found in the sympathetic nervous system (Biedler et 
al., 1973). This cell line has a relatively long doubling time, making them difficult to grow up to a 
large scale. SK N SH are an adherent cell line and so were passaged in the same way as SH SY5Y cells 
and HUVECs. The cells adhere quite sensitively and so, for assays where numerous washing and 
medium changes occurred, the cells were grow on cell culture plates with the Cell+ growth surface 
(Sarstedt, Nümbrecht, Germany). The medium requirements for this cell line were DMEM 
(SigmaAldrich, Missouri, USA) with 2 mM L-glutamine and 10 % FBS. 
 
2.2. Real Time Quantitative Polymerase Chain Reaction (RT-
qPCR) 
 
2.2.1. Sample preparation for the gene analysis of cells treated with 
antagonists and ADM 
 
To analyse the gene expression in SK N SH cells after treatment with antagonists and ADM, cells 
were plated out at a density of 5 x 105 cells per well of a 6 well plate with the Cell+ growth surface 
(Sarstedt, Nümbrecht, Germany). The cells were incubated at 37 °C for 48 hours. The medium was 
aspirated and the cells were washed with PBS before the medium was replaced with serum-free 
DMEM. Cells were pre-treated with 10 µM of antagonist and incubated at 37 °C for 30 minutes. The 
cells were then treated with 0.1 µM of ADM13-52 agonist (GenScript, New Jersey, USA)and incubated 
for 6 hours at 37 °C. RNA extraction was performed as standard.  ADM13-52 acts as an agonist of the 
adrenomedullin receptors and was used due to the degradation of the full ADM peptide. DMSO was 
added to the same concentration as for the samples treated with the antagonist compounds.  
 
2.2.2. RNA Extraction 
 
The medium was aspirated and the cells were washed using PBS. One mL of TRIzol reagent 
(Invitrogen) per 10 cm2 was added to each well. The cells were scraped in the TRIzol and the solution 
was made homogenous using a micropipette. Chloroform was added to the cells at a ratio of 0.2 mL 
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per 1 mL of TRIzol, the sample was shaken vigorously and incubated at room temperature for 2-15 
minutes. After incubation, the samples were centrifuged at 12,000 x g for 15 minutes.  
The samples were separated into three phases containing protein, DNA or RNA. The upper colourless 
aqueous phase contained RNA. This phase was collected and transferred to a tube containing 
isopropanol at a ratio of 0.5 mL to 1 mL of TRIzol used during cell lysis. The sample was incubated at 
room temperature for 5-10 minutes and then centrifuged at 12,000 x g for 10 minutes. The 
supernatant was removed and the RNA pellet was resuspended, using 75 % ethanol at a ratio of 1 
mL per 1 mL of TRIzol initially used. The sample was vortexed and centrifuged at 7,500 x g for 5 
minutes. The supernatant was removed and the RNA pellet was air-dried for 5-10 minutes. Thirty to 
fifty microliters of DEPC-treated TE (Tris-EDTA) buffer was added, with the volume depending on the 
pellet size, and the sample was mixed by micro pipetting. The sample was placed in a heat block at 
55-65 °C for 10-15 minutes.  
The quality of the extracted RNA was then analysed using nanodrop, measuring the A260/A280 ratio to 
check the purity of the RNA. The A260/A280 ratio for pure RNA is around 2.0 however, a ratio of 
around 1.8 is acceptable. The RNA was also analysed using 1 % agarose gel electrophoresis, in order 
to identify any presence of genomic DNA or degraded RNA. 
 
2.2.3. cDNA Synthesis 
 
The extracted RNA was treated with DNase, to degrade the genomic DNA in the sample. This ensures 
the primers, used in the PCR reactions, do not amplify gene sequences from genomic DNA and only 
amplify cDNA sequences. DNase was added to the RNA at a ratio of 0.5 µL to 4 µL sample, containing 
a maximum of 500 ng of RNA, along with 0.5 µL DNase buffer was added, giving a total volume of 5 
µL. The concentration of DNase I used was between 50-375 units/µL according to the supplier 
(Invitrogen, California, USA).  
The sample was gently micro-centrifuged and incubated at 37 °C for 60 minutes. 0.5 µL 0.5 M EDTA 
was added and the sample was gently micro-centrifuged. In order to denature the DNase enzyme, 
the sample was incubated at 65 °C for 10 minutes. 
For the cDNA synthesis reaction, a master mix of: 2 µL cDNA synthesis buffer, 1 µL dNTPs, 0.5 µL 
random hexamers, 0.5 µL Oligo dTs and 0.5 µL reverse transcriptase enzyme (Verso enzyme mix) was 
prepared. In the RT- controls, nuclease free water was added in place of the reverse transcriptase. 
Four µL master mix was added to each RNA sample. The samples were incubated at 42 °C for 60 
minutes and then incubated at 95 °C for 2 minutes. The samples were diluted with nuclease free 
water, to give a 1:5 stock dilution. 
 
2.2.4. Quantitative Polymerase Chain Reaction (RT-qPCR) 
 
The genes investigated using RT-qPCR were ADM (adrenomedullin), RAMP1 (receptor activity 
modifying protein 1), RAMP2, RAMP3, CALCRL (calcitonin receptor-like receptor), CALCA (calcitonin 
gene-related peptide 1) and CFH (complement factor H). Real time quantitative PCR to analyse the 
relative expression of each of the genes in the different cell lines. All of the cell lines were human 
and therefore primers were designed for the human forms of the genes. The primers were designed 
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to be exon-exon spanning so that the primers would only bind to the cDNA of the gene of interest 
and not to full gene sequence of the genomic DNA. The sequences of these primers are given in 
table 2.1, and are presented in the 5ʹ to 3ʹ direction. A housekeeping gene, known to be stably 
expressed in a cell line, was used as a reference gene to normalise expression. The reference gene 
used was GAPDH. GAPDH codes for glyceraldehyde 3-phosphate dehydrogenase, an enzyme 
involved in glycolysis. The primers for the reference gene were purchased as a primer mix 
(containing both the forward and reverse primer) as part of a geNorm kit (Primerdesign Ltd., 
Southampton, UK). GeNorm analysis had previously been used to determine that GAPDH was stably 
expressed in the cell lines used. The gene is one of ten commonly used reference genes 
(Vandesompele et al., 2002).  
For RT-qPCR, the cDNA being analysed was diluted, with nuclease free water, to give a final dilution 
of 1:50. The forward and reverse primers for the target genes of interest were diluted in nuclease 
free water to give a dilution of 1:5. A master mix of nuclease free water, forward primer, reverse 
primer and polymerase-nucleosides master mix (iTAQ) was prepared, at a ratio of 1.4 µL: 0.3µL: 0.3 
µL: 3 µL per well, respectively, for each different gene. Five µL  master mix was added to each well 
the RT-qPCR plate, along with 5 µL cDNA. The plate was centrifuged to mix. 
The RT-qPCR reaction was performed using the CFX96 Touch™ Real-Time PCR Detection System (Bio 
Rad, California, USA). The parameters used for the qPCR reactions were as follows: 30 seconds at 95 
°C to denature the DNA and activate the polymerase, 40 amplification cycles of 5 seconds at 95 °C 
followed by 30 seconds at the annealing temperature of 60 °C, finally melt-curve analysis was 
performed at 95 °C.  
Table 2.1. Sequences of the primers used for real time PCR (RT-qPCR).  
 
Gene Primer direction Sequence 
CALCRL Forward GCTCTGCCCTGATTACTTTCA 
CALCRL Reverse TCTGTTGCTTGCTGGATGTC 
RAMP1 Forward CCCATCACCTCTTCATGACCA 
RAMP1 Reverse CGACGGCCTCCATGTCTAC 
RAMP2 Forward CGCTGTCCTGAATCCCCA 
RAMP2 Reverse GCTGTCTCATAGTTCTTCACCG 
RAMP3 Forward CATGATGGGCAAGGTGGAC 
RAMP3 Reverse CCATCTCGGTGCAGTTGG 
ADM Forward CCAGAGCATGAACAACTTCCA 
ADM Reverse CGACGTTGTCCTTGTCCTTA 
CALCA Forward CAGGAGCAAGAGAGAGAGGG 
CALCA Reverse AGCCGATGAGTCACACAGG 
CFH Forward GGATACCTGCTCCGAGATGT 
CFH Reverse CAGCTACTGGAAAGTATGGTCT 
 
Notes: The Homo sapiens (human) genes are denoted using the standard nomenclature of all capital letters, 
e.g. CALCRL. The primer sequences used for each gene are shown. Sequences are presented in the 5ʹ to 3ʹ 
direction. 
2.3. Adrenomedullin Receptor-Antagonist Compounds 
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The ELF delivered seven of the compounds found to be antagonists of the ADM2 receptor to 
Huddersfield. The compounds and their assigned numbers are listed in Table 2.2. Some of the 
compounds are analogues of other compounds tested during the high throughput screening. The 
parent/analogue relationships of the compounds are described in Table 2.2.  Each compound arrived 
in lyophilized, powder form and was dissolved in DMSO to produce a 10 mM stock solution. The 
stock solutions were stored at -20 °C. All compounds, except for 06 and 04, were white in powder 
form or colourless and clear when in solution. Compounds 06 and 04 were yellow-orange in colour 
when both in powder form and in solution. Compound 08 also developed a yellow tinge in solution 
over time; this may be potentially due to hydrolysis of the compound in storage. The structures of 
the compounds cannot be revealed due to a confidentiality agreement with the ELF. 
Table 2.2. The ADM-receptor antagonist compounds 
 
 
 
 
 
Notes: The ADM-receptor antagonist compounds and their associated names/numbers 
 
 
2.4. Cell viability assays 
 
2.4.1. MTT Assay 
 
The MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, assay is used to measure 
cell viability and can therefore indicate the cytotoxicity of a compound. MTT is a yellow tetrazolium 
dye and is reduced to formazan in the cell by mitochondrial reductases, as well as other cellular 
enzymes (Bernas & Dobrucki, 2002). Formazan forms a precipitate that is dissolved by the addition 
of a solubilisation solution, to form a purple colour. The reaction in which MTT is reduced to 
formazan is shown in Figure 2.1. 
 
Antagonist 
Compound  
Huddersfield Vial 
Number of 
Compound 
Parent/analogue 
14 TC00000014 Parent 
06 TC00000006 Parent 
04 TC00000004 Analogue of 06 
02 TC00000002 Parent 
10 TC00000010 Parent 
08 TC00000008 Analogue of 10 
12 TC00000012 Analogue of a compound 
tested but not sent by 
ELF 
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Figure 2.1. MTT reduction to form Formazan 
Notes: Image was taken from figure 2 of (Desai et al., 2011) 
 
This assay was used to investigate the effects of the compounds on cell metabolism and viability and 
so give an indication of the toxicity of the compounds and so their suitability as a drug. THP-1 cells 
were used as they are monocytes and so to some degree, although not perfectly, replicate the effect 
of the compounds in the blood.  
 
The CellTiter 96 Non-Radioactive Cell Proliferation Assay kit (Promega, Wisconsin, USA) was used to 
perform the MTT assay.  In preparation, THP-1 cells were stimulated with the cytokine, interferon-γ 
(IFN-γ) and plated out on a 96-well plate (Sarstedt, Nümbrecht, Germany) at 100 µL per well. 
Controls of stimulated THP-1 media, but no cells, were also plated out at 100 µL per well. The cells 
were treated with the ADM receptor antagonist compounds at concentrations from 0.002 to 50 µM 
and the plate was incubated for 24 hours at 37 °C. Fifteen µL dye solution was added to each well 
and the plate was incubated for a further 2 hours. One hundred µL solubilisation solution was added 
to each well and the plate was incubated overnight on an orbital shaker. The plate was read at 570 
nm (Tecan Infinite F50 absorbance plate reader).  
After the initial two hours’ incubation, the purple formazan precipitate was visible in the wells 
containing cells. The precipitate dissolves after the addition of the solubilisation solution, giving a 
colour change of the solution in the well from yellow to purple. It was ensured that the precipitate 
was fully dissolved before the plate was read.  
 
2.4.2. CellTiter-Glo Luminescent Cell Viability Assay (Metabolism) 
 
The kit used for cell metabolism assays was the CellTiter-Glo® Luminescent Cell Viability Assay 
(G7572 - Promega, Wisconsin, USA). The assay gives a measurement of the amount of intracellular 
ATP and therefore an indication of cellular metabolism and cell viability. The assay reagent causes 
cell lysis and therefore intracellular ATP to be released. ATP is required for the luminescent reaction 
of the luciferase enzyme, converting luciferin to oxyluciferin. As a result, the greater the 
luminescence signal, the greater the amount of ATP, indicating a higher percentage of viable cells. A 
summary of the reaction is shown in Figure 2.2. 
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Figure 2.2. Principle reaction of the CellTiter Glo assay 
Notes: Image taken from figure 3 of CellTiter-Glo® Luminescent Cell Viability Assay protocol. The luciferase 
enzyme oxidises luciferin to form oxyluciferin. The reaction produces light and uses ATP. Therefore the more 
ATP that is available, indicating more cells are viable, the more light is produced. This means the more viable 
cells there are, the stronger the luminescent signal. 
 
Cells and media were plated out identically to that of the cell proliferation assay in section 2.3, in a 
white bottomed plate. The plate was incubated for 24 hours at 37 °C, as for the proliferation assay. 
One hundred µL CellTiter Glo reagent (prepared from CellTiter Glo substrate and CellTiter Glo buffer) 
was added to each well. The plate was gently shaken for 2 minutes and incubated at room 
temperature (18-25 °C) for 10 minutes. The plate was read using the GloMax® 96 Microplate 
Luminometer, using the pre-set protocol: CellTiter Glo.  
 
2.5. ELISAs 
 
Enzyme-linked immunosorbent assays (ELISAs) are used to quantitatively determine the presence of 
specific substances in cell extracts. The assays work via competition of the specific antigen in the 
sample with a fixed amount of an enzyme-labelled version of the antigen, for the binding sites of the 
primary antibody. The primary antibodies, bound to the antigen, bind to the well of the assay plate, 
which is coated with secondary antibody. Unbound antigen is removed via washing. Any enzyme-
labelled antigen bound to the well, will produce a blue colour when substrate is added, therefore 
the more unlabelled antigen there was in the cell extract sample, the less intense the colour of the 
well will be after incubation with the substrate.  
 
2.5.1. Neopterin ELISA 
 
In preparation for this assay, after treatment with the ADM receptor antagonist compounds, for 24 
hours, THP-1 cells were placed in 1.5 mL Eppendorf tubes and microcentrifuged at 500 x g for 5 
minutes. The pellet was resuspended in 1 mL cold PBS and microcentrifuged for 5 minutes at 1000 x 
g. Cells were lysed using 40 µL RIPA buffer and incubated for 20 minutes on ice or in the refrigerator. 
The samples were centrifuged for 10 minutes at 10,000 x g. The supernatant was transferred to 
clean Eppendorf tubes. The cell extracts were then stored at -80 °C, if not used immediately. 
The kit used for this assay was the Neopterin ELISA (IBL international, ref: RE59321). Twenty µL of 
standard, controls or diluted sample was pipetted into separate wells. Samples are diluted according 
to the protein concentration of each cell extract. To each well, 100 µL enzyme conjugate and 50 µL 
neopterin antiserum was added. The plate was covered with black adhesive foil and incubated at 
room temperature (18-25 °C), on an orbital shaker (at 500 rpm), for 90 minutes.  
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The foil was removed and the solution was discarded from the wells. The plate was washed four 
times with diluted wash buffer (1:20 dilution). After each wash, the excess solution was removed by 
dabbing the inverted plate on paper towel.  
Using a multichannel pipette, 150 µL TMB substrate solution was added to each well. TMB is 
3,3’,5,5’-tetramethylbenzidine, a chromogenic compound used as a substrate for horseradish 
peroxidase in ELISA assays, forming 3,3',5,5'-tetramethylbenzidine diimine which has a blue-green 
colour (Goka & Farthing, 1987). The plate was incubated at room temperature for 10 minutes. The 
substrate reaction was stopped by the addition of 150 µL of TMB Stop solution and the plate was 
gently shaken to mix the contents of the wells. Addition of the stop reagent resulted in a colour 
change of blue-green to yellow, indicating the reaction has stopped.  
The optical density of each well was measured using a photometer at a wavelength of 450 nm, 
within 15 minutes of the addition of the stop solution.  
 
2.5.2. Cyclic AMP ELISA 
 
2.5.2.1. Cell sample preparation 
 
THP-1 cells were pre-treated with either 0.1 µM ADM22-52 (an ADM receptor antagonist) or 10 µM 
ELF antagonist compound, and incubated at 37 °C for 15 minutes. The cells were then treated with 
0.1 µM ADM peptide and incubated for a further 15 minutes at 37 °C.  
For THP-1 samples, the cells were centrifuged at 500 x g for 5 minutes and the medium was removed 
leaving the cell pellet. The pellet was washed with PBS and centrifuged for 5 minutes at 1000 xg. The 
pellet was then resusupended in 120 µL 0.1 M hydrochloric acid (HCl) with 1.0 % Triton X-100. The 
cells were incubated for 10 minutes at room temperature. The lysed cells were centrifuged at 10,000 
x g for 10 minutes and the supernatant was collected. 
For adherent cell lines, media was aspirated and the cells were washed with PBS. 250 µL HCl-Triton 
X-100 was added to the cells and they were incubated for 10 minutes at room temperature. The 
lysed cells were centrifuged at 10,000 x g for 10 minutes, as for THP-1 samples, and the supernatant 
was collected. 
A Bradford assay was performed, using the BioRad protein assay reagent, to determine the protein 
concentration of the samples. The samples were diluted with 0.1 M HCl so that the protein 
concentration of each sample was the same and ≥ 1000 µg/mL.  
 
2.5.2.2. Cyclic AMP Direct Immunoassay 
 
The kit used for this assay was the cAMP direct immunoassay kit (Abcam, Cambridge, UK, ab65355). 
Fifty µL Neutralizing Buffer was added to 100 µL each sample. To this, 5 µL Acetylating Reagent Mix 
(prepared by mixing Acetylating Reagent A with Acetylating Reagent B at a ratio of 1:2) was added to 
each sample and vortexed immediately. The samples were then incubated for 10 minutes at room 
temperature, in order to acetylate the cAMP. Acetylation is important for the recognition of cAMP 
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by the antibody. The acetylating reagents for this reaction are usually acetic anhydride and 
triethylamine. To each sample, 845 µL 1 x Assay Buffer was added to dilute the acetylation reagents, 
giving a final volume of 1 mL and such that each sample was diluted by a factor of 10.  
Samples were added to the Protein G coated plate at 50 µL per well. 10 µL reconstituted cAMP 
antibody was added to each well and the plate was incubated for 1 hour at room temperature, on an 
orbital shaker (set at low speed). Ten µL cAMP-HRP (horse radish peroxidase) was added to each 
well and mixed using a pipette and the plate was incubated for a further hour under the same 
conditions as the previous incubation. The wells were washed 5 times, using 200 µL per well of 1 x 
Assay Buffer for each wash. One hundred µL HRP Developer was added and the samples were 
developed for an hour at room temperature, on an orbital shaker. The samples turned light blue at 
this point. The reaction was stopped using 100 µL 1 M HCl per well, which resulted in a colour 
change from blue to yellow. The plate was read at an OD of 450 nm.  
 
2.6. cAMP-Glo™ Max Assay 
 
The cAMP-Glo Max assay by Promega was used as an alternative assay used to measure cAMP and 
detect changes in cAMP concentration between untreated and treated samples. The assay uses the 
Ultra-Glo Recombinant Luciferase technology of the Cell Titer Glo cell viability assay. The basis for 
the assay is that cAMP activates protein kinase A (PKA), which uses ATP to phosphorylate its 
substrate. The more active the PKA, the less available ATP for the luciferase reaction where luciferin 
is oxidised to oxyluciferin, a reaction that results in luminescence. As a result, a higher concentration 
of cAMP in a sample leads to a lower luminescence value, and vice versa. The principle reactions of 
the assay are summarised in Figure 2.3. As this assay is dependent on ATP levels, it is worth bearing 
in mind that varying ATP concentrations across samples would also have an effect on apparent cAMP 
concentration.  
Cells were counted using a haemoctometer, after first being trypsinised to form single cells in 
suspension and stained using Trypan-blue (Sigma-Aldrich, Missouri, USA). To perform the assay, cells 
were plated out at a seeding density of 105 cells per well of a 96 well white plate and incubated at 
37°C for 24 hours. The media was then aspirated and the cells were washed with 100 µL PBS. The 
cells were treated with 100 µM antagonist compound for 30 minutes at 37°C. The 13-52 peptide 
fragment ADM agonist was added to the cells at a concentration of 1 µM for 30 minutes at 37°C. 
Both the antagonists and the ADM agonist were added to the cells after dilution in complete 
induction buffer consisting of PBS, 50 mM MgCl2, 500 µM IMBX and 100 µM Ro 20-1724 
(phosphodiesterase inhibitors).  
Cyclic AMP detection solution was prepared from Protein Kinase A and cAMP Glo ONE buffer at a 
ratio of 1 in 1000. This was added to the cells at a ratio of 1 to 4 of the treatment solution. The plate 
was gently shaken for 1-2 minutes to mix and incubated at room temperature for 20 minutes. Kinase 
Glo reagent was added to the cells at a volume equal to that of the treatment solution plus the 
cAMP detection solution. The plate was shaken for 1-2 minutes and incubated for 10 minutes at 
room temperature. The luminescence was then read using a luminometer. 
Statistical analyses of the data from both the ELISA and the cAMP assay were performed using the 
GraphPad prism software version 7. P values were calculated to determine the significance of the 
results.  
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Figure 2.3. Principle reactions of the cAMP Glo Max assay 
Notes: Image taken from figure 1 of the Promega cAMP Glo Max assay protocol 
 
2.7. Western Blot 
 
2.7.1. Sample preparation 
 
 
32 
 
SK N SH cells were used as they are a neuronal cell line and express the ADM receptors. Cells were 
plated onto 6 well plates at a seeding density of 5 x 105 cells per well. After 48 hours, the medium 
was removed, the cells were washed with PBS and the medium was replaced with serum-free 
DMEM. The cells were pre-treated with 10 µM ADM-receptor antagonist for 30 minutes. As a 
control, cells in one of the wells were pre-treated with MK2206 (an Akt inhibitor) instead of an ADM-
receptor antagonist. Cells were treated with 0.1 µM ADM13-52 agonist peptide fragment and 
incubated for 1 hour at 37 °C. A control well of cells were also treated with a final concentration of 
0.1 % DMSO, as this was equivalent to the amount of DMSO added to the antagonist treated 
samples.  To harvest the cells, the medium was aspirated and the cells were washed with ice-cold 
PBS. A scraper was used to detach the cells from the surface of the plate and the cell solution was 
made homogenous using a micropipette. The cells were placed in a 1.5 mL Eppendorf and 
centrifuged at 1000 x g for 5 minutes. The supernatant was removed and the pellet was 
resuspended in lysis buffer, consisting of RIPA buffer, 1 % protease inhibitor cocktail and 50 mM 
sodium fluoride (NaF). NaF was used as a phosphatase inhibitor. The samples were incubated on ice 
for 20 minutes. They were then centrifuged for 10 minutes at 10,000 x g. The supernatant was 
removed and placed in a fresh Eppendorf. The protein concentration was determined using the 
Bradford assay. The protein samples were stored at -80 °C. 
 
2.7.2. Western blot 
 
Western blotting was used to analyse FoxO3 and phospho-FoxO3 (Ser253) protein content in the cell 
samples. 10 µg total protein was loaded on to the gel for each sample. The low amount of protein 
was due to difficulties extracting a high concentration of protein from the SK N SH cells. Samples 
were diluted in H2O and 5 µL loading buffer, made using 4 x Laemmli sample buffer (BioRad, 
Hertfordshire, UK) and β-mercaptoethanol (SigmaAldrich, Missouri, USA), to make a total volume of 
20 µL. They were then heated at 100 °C for 10 minutes. 
SDS-PAGE gels were made to the required acrylamide percentage depending on the size of the 
protein of interest. For example, FoxO3 is 71 kDa therefore a gel of 10 % was used, suitable for 
proteins between 15 and 100 kDa. The gels were made using 40 % Acrylamide (BioRad, 
Hertfordshire, UK), 2 % Bis (BioRad, Hertfordshire, UK), Tris-HCl buffer, SDS, Millipore water and 
were set using 10 % ammonium persulfate (APS) (Sigma-Aldrich) and Temed (BioRad, Hertfordshire, 
UK). Samples were run on the gel for around 45 minutes at 35 mA.  
Proteins were then transferred from the gel to a PVDF membrane using a semi-dry transfer 
apparatus (Trans-Blot® Turbo™ Transfer System, BioRad, Hertfordshire, UK). The transfer buffer 
contained 20 % methanol. The transfer process took 35 minutes to complete. 
The membrane was then washed in Tris-buffered saline, 1 % Tween-20 (TBS-T) and blocked using 
SEA BLOCK blocking buffer (ThermoFisher Scientific, Massachusetts, USA) for 1 hour. This blocking 
buffer was chosen over traditional milk powder as milk contains caseins, a family of 
phosphoproteins, which would interfere with the identification of phosphor-FoxO3. The primary 
antibody (specific for the protein of interest) was diluted 1:1000 in the blocking buffer. The primary 
antibodies used for the Western blots are listed in Table 2.3. The membrane was incubated in the 
antibody on a plate rocker overnight on ice. 
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Table 2.3. Primary Antibodies used for Western blots 
 
Antibody Catalogue number 
Phospho-FoxO3a (Ser253) STJ90275 (St John’s Laboratory 
Ltd., London, UK) 
FoxO3a STJ93128 
GAPDH sc-25778 (Santa Cruz 
Biotechnology Inc., Texas, USA) 
 
Notes: All primary antibodies were rabbit IgG polyclonal. The secondary antibody was HRP-conjugate anti-
Rabbit IgG raised in a goat host (ImmunoReagents Inc., North Carolina, USA).  
The membrane was washed 6 times in TBS-T, each wash with a duration of at least 5 minutes. The 
secondary antibody used was HRP conjugated and diluted 1:2000 in blocking buffer. The membrane 
was incubated in the secondary antibody for 1 hour and a plate rocker, at room temperature. The 
membrane was then washed 5 times in TBS-T and once in TBS (no Tween), each wash with a 
duration of 5 minutes. ECL solution (BioRad, Hertfordshire, UK) was prepared by mixing solution A 
with solution B at a ratio of 1:1. The solution was spread evenly over the membrane before imaging.  
 
2.8. Transfection of ADM receptors in SH SY5Y cells 
 
SH SY5Y cells were seeded on a six well plate at a density of 106 cells per well. The cells were 
incubated for 24 hours at 37 °C. The cells were washed with PBS and the medium was aspirated and 
replaced with 2 mL of Opti-MEM (ThermoFisher Scientific, Massachusetts, USA). Polyethylenimine 
(PEI) is a chemical transfection reagent and was used to transfect the cells at a ratio of 2:1 to the 
DNA. A total of 2.5 µg DNA was added to each well, 1.25 µg Calcrl plasmid (Gene Bank Accession 
Number – AY389506) and 1.25 µg of the Ramp2 plasmid (Gene Bank Accession Number – 
AY265458). Plasmids were bought from the cDNA Resource Center, Pennsylvania, USA, with the 
cDNA for each gene having already been cloned into the pcDNA3.1(+) plasmid. PEI and DNA were 
diluted separately in Opti-MEM, then mixed together and incubated at room temperature for 15 
minutes. The PEI:DNA mix was then added to the cells and the cells were incubated for 48 hours at 
37 °C. A plasmid containing GFP cDNA was also used to transfect cells as a control.  
 
3. Results 
3.1. Gene expression in different cell lines 
 
Gene expression was analysed in different cell lines, namely human cell lines HUVEC, SH SY5Y, SK N 
SH and THP-1, using quantitative real-time PCR (RT-qPCR). This was done in order to investigate the 
expression of adrenomedullin (ADM) and its associated genes; the receptor components (CALCRL, 
RAMP2 and RAMP3), the binding protein (CFH), and CGRPα (CALCA) and its receptor (CALCRL and 
RAMP1). Table 3.1 shows the genes expressed in each of the cell lines tested, based on the results 
from the RT-qPCR. Gene expression levels were compared by assigning Cq value ranges with 
symbols. +++ represented a Cq value of 20-25, ++ a Cq value of 25-30, + for 30-35 and - for 35 and 
 
34 
 
Key 
Human 
 
over. In q-PCR, the Cq value represents the cycle number that the fluorescence - which increases as 
the fluorescent dye intercalates in the double stranded DNA fragments, produced from the qPCR- 
exceeds a set threshold. The threshold set for each qPCR was 200 RFU. A Cq value of between 20-25 
was deemed to show high expression of the genes relative to each other as a Cq value of less than 
20 was not achieved for any of the genes in any of the cell lines. A Cq value of over 35 was deemed 
to be so negligible, it was regarded that there was no expression for the particular gene of interest.  
The results show that all of the cell lines express ADM and the ADM1 receptor (CALCRL and RAMP2), 
at least at the transcriptional level, with the exception of human astrocyte cell line, 1321N1. The 
astrocytes analysed appeared to express the CGRP receptor (CALCRL and RAMP1) at a relatively high 
level in comparison to the other cell lines tested, but had little or no expression of RAMP2 and 
RAMP3, suggesting the astrocytes do not express the ADM receptors. Interestingly, astrocytes 
showed high expression of ADM. All of the cell lines, with the exception of HUVEC, appear to express 
the ADM2 receptor (CALCRL and RAMP3) and the CGRP receptor (CALCRL and RAMP1). Despite most 
of the cell lines expressing RAMP1, only RN46A appears to express CALCA, the CGRPα gene. The cell 
lines also express AMBP-1, also known as CFH. There is no data for the expression of CFH in the SH 
SY5Y cell line. 
 
Table 3.1. Expression of ADM and related genes in selected human cell lines 
 
 
 
Notes: Symbols -, +, ++, +++, and N/A represent a Cq value of >35, 30-35, 25-30, 20-25, and no data 
respectively. 
 
3.2. Cell viability and Inflammation 
 
The MTT and CellTiter-Glo assays give an indication of cell metabolism and cell proliferation via 
measurement of ATP, respectively (Stockert et al., 2018; Riss et al., 2013). The assays can therefore 
reveal the effect of treatment with compounds, on cell viability. The results from these assays are 
shown in Figure 3.1. THP-1 cells were treated with 0.02 µM, 0.2 µM, 2 µM, 20 µM and 50 µM and 
incubated at 37 °C for 24 hours. For all of the antagonist compounds, there appears to be no 
significant effect on cell viability at the three lowest concentrations (0.02 µM, 0.2 µM and 2 µM) 
shown by the linear horizontal section of the graph at around 100 % of the maximum interassay 
response, at these concentrations. 
 Gene 
Cell line CALCRL RAMP1 RAMP2 RAMP3 ADM CALCA CFH 
HUVEC +++ - ++ - ++ - ++ 
SH SY5Y + ++ ++ ++ ++ - N/A 
SK N SH + +++ ++ ++ ++ - ++ 
THP-1 + + + ++ + - + 
Astrocyte 
- 1321N1 ++ +++ - + +++ ++ +++ 
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For compounds TC14, TC04, TC08, TC10 and TC12, the viability of the cells had decreased after 
treatment with 20 µM of compound and had further decreased after treatment with 50 µM, to a 
minimum of around 50 % of that where the cells were not treated with compound. For the 
compounds 06 and 02, there was also a decrease in cell viability at the higher concentrations of 20 
µM and 50 µM, however the decrease was much more rapid and the cell viability was reduced to 
almost 0 %, suggesting the cells were no longer viable after treatment with the higher 
concentrations. Bradford assays of THP-1 cell lysates after the cells were treated with the 
compounds TC02 and TC06, showed that the protein concentrations after cells were treated with 
the higher concentrations of 20 µM and 50 µM were much lower for these compounds compared to 
the other compounds at the same concentrations (∼ 3 times lower).  
Upon stimulation with IFN-γ, THP-1 cells produce neopterin. Neopterin is associated with an immune 
response and inflammation, therefore neopterin release from THP-1 after induction by IFN-γ is a 
model of inflammation. A neopterin ELISA was performed on THP-1 cells stimulated with IFN-γ and 
treated with the five concentrations of the seven different compounds, incubated at 37 °C for 24 
hours, in order to determine the effect of the drugs on inflammation.  
For compounds TC14, TC04 and TC12, the graphs for the neopterin ELISA show that the % maximum 
interassay response is horizontal linear across the increasing concentration of the compounds. This 
suggests these compounds have no effect on inflammation or the pathway involved in neopterin 
production (the BH4 pathway).  
Compounds TC02 and TC06 appear to reduce the amount of neopterin produced, at the higher 
concentrations of 20 µM and 50 µM, to almost 0 % of that produced where no compound had been 
added. This suggests an ability for the compounds to reduce inflammation. However, taking into 
account the results from the viability assays, this reduction in neopterin is more likely to be due to 
cell death caused by the compounds at high concentrations. The percentage response was 
significantly negatively correlated to the concentration of the compound TC02 (p-value = 0.03). This 
suggests that the level of neopterin decreased as the concentration of compound TC02 increased.  
Treatment with compounds 10 and 08 appears to result in an increase in neopterin at high 
concentrations, with the maximum amount of neopterin produced achieved at 50 µM of compound. 
This suggests that these antagonist compounds may increase or cause inflammation via the 
neopterin pathway. The relative percentage of neopterin produced was significantly positively 
correlated to the concentration of compound TC10 (p-value = 0.04). This suggests that the level of 
neopterin increased as the concentration of compound TC10 increased. 
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Figure 3.1. The effects of ADM receptor-antagonist compounds on cell viability and inflammation 
THP-1 cells were treated with 0.02 µM, 0.2 µM, 2 µM, 20 µM or 50 µM of the antagonist compounds for 24 
hours. The effects of the antagonist on cell viability were measured using the MTT and Cell Titer-Glo assays. A 
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neopterin ELISA was used to indicate any inflammation caused by the addition of the antagonists. For the 
neopterin assays, the percentage response was a measurement of the amount of neopterin, with 100 % being 
the maximum amount of neopterin obtained for a sample treated with a given compound. For the MTT and 
Cell Titer Glo assays, the percentage response was the percentage of cells viable, with 100 % being the 
maximum percentage of viable cells compared to the control for a given compound.  Maximum interassay 
response refers to the relative percentage of response from the assay with 100 % being the max response 
from any of the assays at any given concentration of compound. This allows a comparison between the 
different assays.  
 
3.3. Cyclic AMP levels 
 
3.3.1. cAMP ELISA 
 
A cAMP ELISA (cAMP Assay Kit - Direct Immunoassay, Abcam, Cambridge, UK, ab65355) was used to 
measure the concentration of cAMP in cell samples treated with 0.1 µM ADM and 0.1 µM ADM with 
10 µM ADM receptor antagonist compounds or 0.1 µM peptide antagonist, ADM22-52.  The cell lines 
used in this initial ELISA were THP-1, SH SY5Y and the human astrocyte cell line, 1321N1. These cell 
lines were chosen based on the gene expression analysis results shown in Table 3.1. The gene 
expression analysis suggested that the cell lines expressed at least one of the ADM receptors. The 
aim of this ELISA was to test for the presence of a functional ADM receptor that could activate the 
Gαs protein and therefore, stimulate cAMP production. The ELISA would also suggest which of the 
antagonist compounds could inhibit the ADM receptor most effectively.  
The results of the ELISA are shown in Figure 3.2. The concentration of cAMP was very low in most of 
the samples, with some samples having a cAMP concentration lower than the range of the cAMP 
standard and therefore these results are not accurate. There was also a lot of variation between 
sample repeats, resulting in large error bars. The THP-1 samples had a higher average concentration 
of cAMP than for the SH SY5Y and astrocyte samples. The average cAMP concentration of the THP-1 
samples was 7.71 fmol/µL, whereas the average for SH SY5Y and astrocyte samples (excluding 
samples stimulated with forskolin) was 0.124 fmol/µL and 0.572 fmol/µL respectively.  This may be 
due to the possibility that the THP-1 RPMI media may contain cAMP (>350 fmol/µL), according to 
the assay protocol (Abcam, Cambridge, UK), and some of the cAMP might have remained in the 
samples.  
To act as a positive control, cells were treated with 5 µM forskolin, with no ADM. Forskolin is an 
activator of adenylate cyclase and so should stimulate an increase in intracellular cAMP. Forskolin 
treatment successfully increased cAMP in SH SY5Y and astrocyte cells. The graph appears to show 
that cAMP levels have decreased in astrocytes treated with Forskolin however, this is due to the 
‘negative’ values achieved for the concentration of cAMP in the untreated control, resulting in an 
apparently negative percentage cAMP value for the Forskolin treated cells. The average cAMP 
concentration for SH SY5Y cells and astrocytes stimulated with forskolin was 32.6 fmol/µL and 40.1 
fmol/µL respectively. However, forskolin failed to increase intracellular cAMP levels in THP-1 cells.  
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Figure 3.2. Initial cAMP ELISAs for different cell lines treated with ADM and the receptor antagonists 
Results from the initial cAMP ELISA, measuring cAMP concentrations in THP-1, SH SY5Y and astrocytes treated 
with 0.1 µM ADM and 10 µM of the antagonist compound. Cells were also treated with 10 µM forskolin as a 
positive control. There were three technical replicates for each sample. 
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3.3.2. cAMP-Glo Max Assay 
 
The cAMP Glo Max assay (Promega, Wisconsin, USA, V1681) was used to measure cAMP after 
difficulties with the ELISA, involving presumed degradation of the IgG proteins on the assay plate 
meaning the kit could not be stored (contrary to the manufacturer’s protocol). SK N SH cells were 
chosen due to their expression of the ADM receptors shown in the gene expression analysis (Table 
3.1). The cells have also been shown to express the ADM receptors by Xu and Krukoff in 2005 (Xu & 
Krukoff, 2005). Human umbilical vein endothelial cells (HUVECs) were originally chosen as they only 
express the ADM1 receptor and not the CGRP receptor. However sufficient cells required for the 
assays could not be cultured and maintained efficiently.  
Results from the first biological replicate (Figure 3.3) suggest that TC14 and TC02 are the only two 
antagonist compounds to have greatly inhibited ADM-mediated intracellular cAMP increase. Cells 
treated with 1.0 µM ADM only had an intracellular cAMP concentration of 31.3 nM, whereas cells 
pre-treated with 100 µM TC14 or TC02 had intracellular cAMP concentrations of 0.7 nM and 5.3 nM 
respectively. TC04 appears to have the opposite effect on cAMP concentration, apparently 
increasing cAMP even further than ADM. The intracellular cAMP concentration of cells pre-treated 
with 100 µM TC04 was 42.0 nM.  
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Figure 3.3. Intracellular cAMP concentration after treatment with ADM and receptor antagonists – First biological 
replicate 
Intracellular cAMP concentrations of SK N SH cells treated with 1.0 µM ADM for 30 minutes after pre-
treatment with 100 µM of the indicated ADM receptor antagonist compound. This was the first biological 
replicate with three technical replicates for each sample. To the DMSO control, 1 % DMSO was added to the 
cells, as this is equivalent to the total amount of DMSO in the samples treated with antagonist.  
These results were not reproduced when the assay was performed again. The second biological 
replicate (Figure 3.4) produced results with large error bars and ADM does not appear to have 
stimulated cAMP production in the ADM only sample. The concentration of cAMP in the samples 
treated with ADM and 100 µM antagonist appears to have increased, suggesting ADM has 
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stimulated cAMP synthesis in these samples. The cells treated with TC04 seem to have a higher 
concentration of cAMP than the other samples as was seen in the results of biological replicate one. 
Other than this, none of the samples have replicated the results obtained from the first replicate. 
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Figure 3.4. The second biological replicate of the cAMP-Glo Max assay 
This was the second biological replicate with three technical replicates for each sample. The assay conditions 
were the same as for the first biological replicate. 
 
3.4. Gene expression in SK N SH cells treated with antagonists 
and ADM 
 
The expression of the ADM1 receptor genes (CALCRL and RAMP2) and cyclin B1 (CCNB1) was 
investigated using RT-qPCR. SK N SH cells were treated with ADM13-52 only or ADM13-52 after pre-
treatment with one of the antagonist compounds.  Analysis of the expression of the ADM1 receptor 
genes (graphs a and b, Figure 3.5) suggest both of the receptor genes may be down regulated in cells 
treated with ADM. The expression of CALCRL and RAMP2 in ADM-treated cells has decreased to 
around 0.5 relative to their expression in non-treated cells. The pre-treatment of cells with an 
antagonist compounds appears to have abrogated the decrease in expression to varying degrees for 
each compound. The error bars are large therefore it is difficult to determine, with certainty, which 
compounds were most effective at preventing the decrease in expression of the receptor genes. 
However, it does appear that compounds TC - 02, 10, 08 and 12 (for CALCRL) and TC – 04, 02, 10, 08 
and 12 (for RAMP2) were most effective at blocking the decrease in expression, bringing the 
expression to around that of the non-treated cells. TC14 and TC06 have resulted in a higher 
expression of the receptor genes than in cells treated with ADM alone, however the expression is 
still lower than that in the non-treated cells. In regards to CALCRL expression, TC04 has also failed to 
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bring the expression back to the level of the non-treated cells. Again, there are large error bars, 
particularly for TC14, which overlap the non-treated cell expression. Therefore, TC14 may have also 
brought the expression of the genes back to the non-treated level. 
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Figure 3.5. Relative expression of ADM1 receptor genes (CALCRL and RAMP2) and Cyclin B1 (CCNB1) 
SK N SH cells were pre-treated with 10 µM of antagonist for 30 minutes and treated with 0.1 µM of ADM13-52 
agonist peptide for 6 hours. Quantitative PCR was performed on two technical replicates for each sample, in 
duplicate. Gene expression was normalised to a reference gene (GAPDH) and expression in the treated 
samples was compared to that of the non-treated control. 
The expression of cyclin B1 (CCNB1) (graph c, Figure 3.5) also appears to have been reduced by 
ADM-treatment, to around 0.6 of the expression in non-treated cells. Paradoxically, in cells pre-
treated with TC14, CCNB1 expression is even lower at 0.5. Pre-treatment with TC02 however, 
appears to have resulted in the expression of cyclin B1 back to around 0.75 of that of non-treated 
cells.  
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3.5. Western Blot 
 
One of the project aims was to investigate potential alternative pathways involved in ADM-mediated 
activity, and investigate the hypothesis that the neuroprotective effect of ADM is dependent on 
FoxO3a phosphorylation.  
On the manufacturer’s website (www.stjohnslabs.com – accessed 19/07/18, STJ93128) it states that 
FoxO3a has a molecular mass of 97/71 kDa and shows the antibody producing a band at around 70 
kDa and 85 kDa on two different Western blots using different cell lines. Based on this it is 
reasonable to assume that the bands indicated with arrows in Figure 3.6, between 75 and 100 kDa, 
correspond to FoxO3a. There are also a number of other, fainter bands at lower molecular masses 
and dark dots across the membrane suggesting non-specific binding. Due to the bands being unclear, 
it is difficult to make any obvious conclusions on the comparison of the levels of FoxO3a between 
the different samples. Analysis based on the intensity of the bands, using the image report function 
of the Image Lab software (BioRad, Hertfordshire, UK), suggested that the level of the housekeeper 
protein GAPDH was even across the different samples. The standard deviation of the intensity of the 
GAPDH bands was 0.08 where the average of the band intensities is defined as 1.  
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Figure 3.6. FoxO3a* in SK N SH cells treated with ADM and antagonist 
1 – Non-treated, 2 – DMSO (antagonist vehicle), 3 – ADMa only, 4 – TC14 + ADM, 5 – TC06 + ADM, 6 – TC04 + 
ADM, 7 – TC02 + ADM, 8 – TC10 + ADM, 9 – TC08 + ADM, 10 – TC12 + ADM, 11 – MK2206 (Akt  inhibitor) + 
ADM, 12 – SC79 (Akt activator). The arrows indicate the band believed to correspond to the FoxO3a protein. * 
- Not phosphorylated at the site S253; the antibody was raised around the non-phosphorylated S253 site. a –
the agonist used was the ADM13-52 peptide fragment 
The manufacturer’s website (www.stjohnslabs.com – accessed on 19/07/2018, STJ90275) shows a 
band between 75 and 50 kDa labelled as pFoxO3a and states that the molecular mass of the protein 
is 71 kDa. Therefore, the bands indicated with the arrows in Figure 3.7 are likely to correspond to p-
FoxO3a. Protein from the same samples used in the blots in Figure 3.6 was used in the Western blots 
in Figure 3.7 where FoxO3a phosphorylated at the serine 253 site was the protein of interest. All four 
gels for the Western blots were run simultaneously. As with the blots in Figure 3.6, the bands on the 
blots in Figure 3.7 are faint and, although obviously present, they are not clearly defined. This makes 
it quite unclear of any differences between the samples in terms of the level of FoxO3a 
phosphorylation. There are also a number of different bands visible aside from the one predicted to 
represent P-FoxO3a. This could be a result of non-specific binding due to the antibodies being 
polyclonal and potentially binding to an analogue of FoxO3a.  
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Figure 3.7. Phosphorylated FoxO3a (S253) in SK N SH cells treated with ADM and antagonists 
1 – Non-treated, 2 – DMSO (antagonist vehicle), 3 – ADMa only, 4 – TC14 + ADM, 5 – TC06 + ADM, 6 – TC04 + 
ADM, 7 – TC02 + ADM, 8 – TC10 + ADM, 9 – TC08 + ADM, 10 – TC12 + ADM, 11 – MK2206 (Akt inhibitor) + 
ADM, 12 – SC79 (Akt activator). The arrows indicate the band believed to correspond to the P-FoxO3a. a –the 
agonist used was the ADM13-52 peptide fragment 
The results of densitometric analysis of the bands corresponding to either FoxO3a or P-FoxO3a 
compared to the bands corresponding to GAPDH, for each sample, are shown in Figure 3.8. The 
intensity of each band was obtained using the image report function of Image Lab software, 
mentioned previously.  The results show the ratio of P-FoxO3a to FoxO3a in its unphosphorylated 
form (as the antibody used bound at the unphosphorylated Ser 253 site). The ratios for samples 7 to 
12 are extremely low, with a range of just 0.03 to 0.1, suggesting a very low amount of P-FoxO3a 
compared to FoxO3a in these samples. The ratios for samples 1 to 6 are much larger, with a range of 
0.3 to 1.3. For the non-treated control, the ratio of P-FoxO3a to FoxO3a is 0.4 and for the DMSO 
control the ratio is slightly higher at 0.75 suggesting that, when not treated with ADM or antagonist, 
more FoxO3a is in the unphosphorylated form than is in the phosphorylated form in the cell. Cells 
treated with ADM had a ratio of 1.3, suggesting that there is more P-Foxo3a to unphosphorylated 
FoxO3a and so it appears that ADM has resulted in the phosphorylation of FoxO3a. It is difficult to 
compare the effects of the antagonists on the ratios P-FoxO3a to unphosphorylated FoxO3a due to 
the low ratios for samples 7 to 12, which include the samples of cells treated with TC02, TC10, TC08 
and TC12. The ratios for the cells treated with antagonists are lower than or around the same as the 
ratios for the controls, except for TC04, at 0.8 or below. TC14 has the highest ratio for the 
antagonists, at 0.8, but is still around the same as the DMSO control ratio of 0.75. However, TC04 
has a higher ratio of P-FoxO3a to unphosphorylated FoxO3a than the controls, at 1.2, almost the 
same as the ratio for the ADM treated sample. The P-FoxO3a ratio is 0.03 in cells treated with the 
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Akt inhibitor, MK2206, but higher in cells treated with the Akt activator, SC79, at 0.06. No statistical 
analysis could be performed as the Western blot was only successfully performed once. 
 
 
 
Figure 3.8. Densitometric analysis of Western Blots to show ratio of P-FoxO3a to Unphosphorylated FoxO3a 
 
 
3.6. Transfection of ADM receptors in SH SY5Y cells 
 
The SH SY5Y cells transfected with the GFP plasmid as a control were analysed using a microscope, 
under blue light. These cells were green fluorescent, indicating the transfection of these cells was 
successful. Protein was harvested from all of the cell samples, transfected with the different 
plasmids.  Western blot analysis using antibodies specific for RAMP2 and CLR did not show any 
bands for any of the samples.  
  
4. Discussion 
 
4.1. Cell Viability and Inflammation 
 
The effect of the compounds on cell viability and the induction of inflammation was assessed, before 
investigating their ability to inhibit ADM-mediated signalling activity. This was done using the MTT, 
Cell-titer Glo and Neopterin ELISA assays, and using THP-1 cells. THP-1 cells were used as they are 
relatively easy to maintain and grow. Furthermore, they are also of a haemopoietic lineage and so 
should give an indication of how the compounds would affect the body when they first enter the 
bloodstream. The results of the cell viability assays, MTT and Cell-Titer Glo, show that for all seven of 
the ADM receptor antagonist compounds there has been a reduction in cell viability at the highest 
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two concentrations of compound (20 µM and 50 µM). This suggests that at a concentration of 
between 10 µM and 20 µM the compound begins to cause cell death. Statistical analysis showed 
that there was no significant correlation between the concentration of compound and cell viability 
(p-values >0.05), supporting that the compounds do not cause cell death at lower concentrations. 
The apparent sudden induction of cell death at a concentration of between 10 µM and 20 µM 
suggests that cell mechanisms may be able to prevent damage caused by the compound, up until a 
threshold concentration is reached. At this point apoptosis would be triggered. A possible 
explanation for this could be that the compounds result in the induction of reactive oxygen species 
(ROS) in the cell, as cells are equipped to neutralise ROS up to a certain threshold. The purpose of 
the neopterin ELISA was to assess the effect of the compound on inducing inflammation, as 
neopterin is a pro-inflammatory marker. For compounds TC14, TC04, TC08 and TC12 the level of 
neopterin remains almost constant across the range of concentrations. This suggests these 
compounds had no effect on neopterin production and so no apparent effect on inflammation (p-
values > 0.05). For compound TC06 the level of neopterin appears to be reduced at the higher 
concentrations of 20 µM and 50 µM, suggesting the compound has reduced inflammation. However, 
TC06 resulted in the largest reduction in cell viability at these higher concentrations. In addition, the 
p-value was > 0.05, suggesting no correlation between the compound concentration and neopterin 
level. Therefore the observed reduction in neopterin is likely to only be a result of cell death rather 
than a specific reduction in the production of neopterin. Treatment with compound TC02 has also 
resulted in a large decrease in cell viability and an apparent large decrease in neopterin production. 
However, unlike for compound TC06, a reduction in neopterin is apparent at a concentration of 10 
µM. This is lower than the concentration where a reduction in cell viability is first observed, 
suggesting the reduction in neopterin is not just a result of cell death but rather a reduction in 
neopterin synthesis. This is supported by statistical analysis, showing a p-value of 0.03, suggesting 
there is a correlation between the concentration of TC02 and the level of neopterin. It is possible 
that compound TC02 affects the BH4 pathway, a pathway associated with neopterin synthesis. This 
finding is significant as it implies compound TC02 could reduce inflammation and affect the immune 
response. On the other hand, compound TC10 appears to increase neopterin levels. Statistical 
analysis gave a p-value of 0.04 suggesting a correlation between the concentration of the compound 
and neopterin levels. This suggests that compound TC10 results in increased inflammation and may 
elicit an immune response. This is not an ideal property for a therapeutic, particularly in the 
treatment of MDD which has been linked to inflammation. In particular, increased levels of pro-
inflammatory markers seem to increase the probability that a patient will not respond to anti-
depressant treatment (Eller et al., 2008). On the other hand, the ability of compound TC02 to reduce 
inflammation could therefore potentially be beneficial, if the compound could be used as a 
therapeutic in MDD. 
4.2. Expression of the ADM Receptors 
 
Several factors have made completing the main objectives of the project more difficult than 
expected. One difficulty faced has been finding a cell line that both expresses the ADM receptors 
and does not express the CGRP receptor. After analysing cDNA from seven different cell lines 
(section 3.1), it appeared that HUVEC was the best candidate to fit these criteria. HUVECs only 
express the Calcrl and Ramp2 genes, therefore only the ADM1 receptor. This was not surprising as 
ADM is a vasodilator and so the expression of its most specific receptor in endothelial cells would be 
expected. However upon culturing HUVECs, it became apparent that the cells do not grow very 
quickly or to a high passage number. This made it difficult to grow enough cells for the desired 
47 
 
assays. Endothelial cell growth medium is also relatively expensive compared to other growth 
media; therefore growing the cells on the scale required would not have been sustainable. In 
addition, endothelial cells are not the most appropriate cell line in the context of this project, as they 
are not particularly relevant to MDD.  
Based on the gene expression analysis (Table 3.1), SH SY5Y and THP-1 cell lines appeared to express 
the ADM receptors and CGRP receptor, whereas the astrocyte cell line - 1321N1 appeared to mainly 
express the CGRP receptor. However, the cAMP ELISA results (section 3.3.1) showed that ADM did 
not stimulate an increase in intracellular cAMP levels in these cell lines. This suggests that, although 
CALCRL and the RAMP genes are being expressed, this is not translating to the formation of a 
functional receptor capable of being activated by an ADM peptide agonist. This may be because the 
translational or post-translational processes involved in the receptor formation require machinery 
not present in these cell lines or are being downregulated in by unknown factors.  
The SK N SH cell line seemed to express CALCRL and all three RAMP genes in the gene expression 
analysis (section 3.1.).  ADM stimulation had also previously been shown to increase nitrite and 
intracellular cAMP levels in SK N SH cells (Xu & Krukoff, 2005), suggesting the presence of ADM 
receptors. The cell line is dopaminergic neuronal and so is relevant in the context of MDD. For these 
reasons, SK N SH was chosen as the next cell line to investigate ADM-mediated activity.  
 
 
4.3. ADM-Mediated cAMP Production and the Effects of Antagonist Pre-
Treatment 
 
Measurement of cAMP levels using the cAMP ELISA (Abcam, Cambridge, UK) could not be repeated, 
due to the rapid degradation of the plate once opened. Therefore, the cAMP-Glo Max assay was 
used for further experiments. Similarly to HUVECs, SK N SH are quite slow growing cells and do not 
appear to reach a high level of confluency. However, for this assay, it was possible to grow enough 
cells to perform each repeat. A small-scale test involving only non-treated and 1.0 µM ADM13-52 
treated SK N SH cells confirmed that ADM increased intracellular cAMP in this cell line.  
ADM is an unstable peptide, with a half-life of just minutes (Hinson et al., 2000). It is thought that 
the peptide had degraded in storage at -80 °C, in PBS buffer. This was because the full length ADM 
peptide was able to stimulate cAMP level increase immediately after reconstitution in PBS buffer 
prior to freezing, but aliquots that had been frozen no longer had an effect on cAMP levels. This was 
also assumed to be true for the ADM22-52 antagonist peptide. As a result, for experiments involving 
SK N SH cells (the cAMP-Glo Max assay and Western Blots) the ADM13-52 peptide fragment was used 
as an agonist and the ADM22-52 peptide could not be used as a known antagonist control, as was 
originally planned. 
For the cAMP Glo Max assay, a calculating error meant that the cells were pre-treated with a 
concentration of 100 µM of antagonist compound, instead of the intended 10 µM. 10 µM was 
originally chosen because at this concentration no cell death was observed, for any of the 
compounds, in the cell viability assays. Despite the high concentration of antagonist actually added 
to the cells, the assay appears to have been successful for the first biological cell replicate. There is 
nothing to suggest that cell death may have occurred, as would be expected from the results of the 
viability assay. This may be due to a different cell line being used in this assay compared to the 
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viability assays. However, it may be to be due to the cells in the cAMP Glo Max assay only being 
exposed to 100 µM of compound for around 1 hour in total, whereas in the viability assays the cells 
were exposed to the compounds for 24 hours. For the cAMP assay, the cells were pre-treated with 
antagonist compound to ensure the antagonists to bind to the ADM receptors before ADM agonist 
was added and reach dissociation equilibrium. ADM agonist was added at a concentration of 1.0 µM 
to ensure the maximum response was reached, based on the literature (Hay et al., 2004). The time 
chosen for ADM agonist stimulation was 30 minutes as this was considered long enough to activate 
the ADM receptor and stimulate adenylate cyclase to produce cAMP. This decision was made based 
on the literature (Nikishimi et al., 1998; Shimekake et al. 1995) and seemed effective. When treated 
with ADM agonist and each of the different antagonist compounds (section 3.3.2), only the 
compounds TC02 and TC14 greatly reduced cAMP. TC14 in particular has reduced the concentration 
of cAMP almost to 0 nM. There is concern that the decrease in cAMP may be due to cell death as the 
compounds TC02 and TC06 showed significant reduced cell viability at higher concentrations of 20 
and 50 µM (section 3.2.), and the concentration of compound used in the cAMP assay was higher 
than this at 100 µM. However, TC06 does not show decreased cAMP as would be expected if the 
reduction of cAMP was due to cell death rather than inhibition of ADM activity. Cell death would 
also not explain the results shown for TC14, as the compound did not show a large reduction in cell 
viability at higher concentrations. It is worth noting that the cells used for the viability assay were of 
the THP-1 cell line and not SK N SH so it might be that TC14 affects SK N SH viability and not THP-1 
viability and likewise TC06 affects THP-1 viability but not SK N SH viability, but this seems unlikely. 
Interestingly, TC04 appears to have resulted in a slight increase in cAMP compared to cells treated 
with ADM alone. It may be that some property of the structure of the TC04 compound is affecting 
luminescence. It is unlikely that the compound would produce luminescence by itself. Another 
explanation for the increase of cAMP caused by TC04 is that the compound could bind to ADM and 
result in a conformation more favourable for receptor binding and/or activation. A further 
explanation would be that TC04 can stimulate cAMP synthesis independently of ADM either via the 
ADM receptor or a different mechanism. The latter could explain why the ELF report did not pick up 
on the ability of TC04 to increase cAMP, because their experiments used cell lines with the ADM2 
receptor stably transfected into the cells and TC04 maybe be acting on a pathway not present in 
these cells but present in SK N SH cells. To investigate this the concentration of cAMP should be 
measured in cells treated with TC04 in the absence of ADM.  
The results of the cAMP-Glo Max assay could not be statistically analysed to prove their significance 
as there were only two biological replicates performed. However, the results from the first biological 
replicate (Figure 3.3) showed quite clearly that the compounds TC14 and TC02 inhibited the 
stimulation of cAMP synthesis by the ADM agonist peptide. The error bars for the results of the first 
biological replicate are small, certainly much smaller than the error bars for the results for the 
second biological replicate (Figure 3.4). This suggests the results for the first replicate are more 
precise and more reliable, and so probably more accurate than the second replicate. However this is 
not a certainty as the assay may have intrinsic background noise and thus correct data could have 
large error bars in this instance. Despite this, I believe the first replicate is more likely to be correct 
based on many previous experiments in the literature, referenced throughout this thesis, strongly 
supporting that ADM is able to increase cAMP levels in cells. The assay was performed for a third 
time but the results were even more variable than for the second replicate. Based on this, it may be 
that the kit is most reliable immediately after the initial preparation of the reagents, despite storing 
unused reagents as specified by the protocol.  
A possible explanation for only TC14 and TC02 showing significant inhibition of the ADM-mediated 
increase in the intracellular cAMP concentration is that the ADM peptide was in fact stimulating the 
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CGRP receptor. Due to cross specificity across the receptors, ADM can also act as an agonist for the 
CGRP receptor.  Gene expression analysis (Table 3.1) showed that SK N SH express all three RAMP 
genes and RAMP1 (the RAMP component that forms the CGRP receptor along with CLR) appears to 
be expressed at the highest level. It could be that the cAMP increase observed upon ADM treatment 
is a result of the collective stimulation of all three of the receptors. However ELF only tested the 
antagonist compounds against the ADM2 receptor and so the specificity of the compounds for the 
CGRP receptor and the ADM1 receptor is unknown. It may be that TC14 and TC02 are more specific 
for the CGRP receptor and, as this is the receptor that appears to be most highly expressed in SK N 
SH, the inhibition of increased cAMP was most apparent in cells treated with these antagonist 
compounds.  
4.4. Gene Expression of Cells Treated with the Antagonists  
 
The results of the gene expression analysis of SK N SH cells treated with the antagonists and ADM13-
52 (graphs a and b, Figure 3.5) suggest that treatment with ADM agonist alone may result in 
decreased expression of the ADM1 receptor genes (RAMP2 and CALCRL). There are large error bars 
for some of the samples; this may be because, due to time constraints, only one biological replicate 
was analysed. Analysis of further biological replicates should reduce overall variability between the 
samples and allow statistical analysis, increasing the reliability of the results. ADM decreasing the 
ADM1 receptor at the transcriptional level suggests an auto negative feedback mechanism for the 
peptide. This would provide regulation during ADM signalling pathways. The ability of the 
compounds to abrogate the decrease in receptor expression suggests that the compounds 
successfully blocked ADM signalling.  
The expression of cyclin B1 (CCNB1) in SK N SH cells treated with ADM13-52 alone or pre-treated with 
either TC02 or TC14 was analysed, as CCNB1 is a gene thought to be down regulated by FoxO3a. It 
would be expected that, if ADM inhibits FoxO3a transcriptional activity, cells treated with ADM 
would have increased CCNB1 expression. However, the results of the expression analysis for CCNB1 
(graph c, Figure 3.5) suggest that CCNB1 expression has decreased in cells treated with ADM agonist. 
Furthermore, pre-treatment with the antagonist TC02 resulted in some rescue of CCNB1 expression 
supporting that ADM signalling resulted in the decreased expression. However, this cannot be 
certain as cells pre-treated with TC14 had an even lower level of CCNB1 expression than non-treated 
cells. Analysis of more biological replicates are needed to confirm the results. The compounds TC14 
and TC02 were chosen as they were the antagonist compounds with the greatest effect on ADM-
mediated intracellular cAMP levels (Figure 3.3). Interestingly, TC02 was successful in blocking the 
ADM-mediated changes in expression of all three of the genes investigated, supporting the 
compound’s ability to antagonize ADM-signalling. However, TC14, which was the antagonist 
compound most effective at inhibiting ADM-mediated cAMP increase, was one of the least effective 
compounds at blocking the decrease in ADM1 receptor expression and completely failed to block the 
decrease in CCNB1 expression. However, the concentration of antagonist during the cAMP-Glo Max 
assay was 100 µM whereas the concentration during pre-treatment for RNA extraction was only 10 
µM and so this may explain the difference in effectiveness for TC14.  
If ADM signalling does result in decreased cyclin B1 expression, this would give evidence to reject the 
hypothesis that ADM mediates FoxO3a phosphorylation and inhibits FoxO3a transcriptional activity. 
It may even mean that ADM in fact increases FoxO3a transcriptional activity. On the other hand, 
other factors are likely to be involved in cyclin B1 expression independent of FoxO3a and may have 
counteracted any effect the inhibition of FoxO3a would have on the expression of this gene.  The 
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original analysis of FoxO3a transcriptional regulation was done in DLD1 colon carcinoma cells 
(Eijkelenboom et al., 2013) and so FoxO3a may affect genes differently in different cell types. Also, 
ADM treatment, before RNA extraction, was 6 hours in duration and therefore phosphorylation of 
FoxO3a by ADM-mediated signalling may have ceased by this point. FoxO3a activity may even have 
temporarily increased to compensate for the inhibition, resulting in the observed decrease in CCNB1 
expression.  To investigate this further, the effect of ADM on the other FoxO3a regulated genes 
could also be analysed. The effect of ADM stimulation on CCNG2 could be investigated as this was a 
gene found to be upregulated by FoxO3a (Eijkelenboom et al., 2013). If the expression of this gene is 
upregulated by ADM, as the results suggested CCNB1 was downregulated by ADM, this could further 
challenge our hypothesis of the effect of ADM on FoxO3a activity.  A more effective way to look at 
the direct effect of ADM treatment on FoxO3a phosphorylation would be by Western blot analysis.  
4.5. ADM-Mediated FoxO3a Phosphorylation 
 
It was only possible to perform Western blot analysis for FoxO3a and P-FoxO3a, successfully, once. 
The densitometric analysis of these blots shown in Figure 3.8, seems to suggest that ADM 
successfully stimulated the phosphorylation of FoxO3a. This is shown by the ADM-only treated cells 
having a ratio of P-FoxO3a to unphosphorylated FoxO3a clearly higher than that for non-treated cells 
and cells treated with DMSO only. The ratio is also higher than 1.0 in ADM-only treated cells, 
suggesting these cells have more FoxO3a in its phosphorylated form than in its unphosphorylated 
form. This supports the hypothesis that ADM mediates the Akt-dependent phosphorylation of 
FoxO3a. Interestingly, TC04 pre-treated cells had a P-FoxO3a ratio that was also above 1.0, whereas 
cells pre-treated with the other antagonists had ratios around the same or below the ratio values of 
the controls. This seems to support the results shown in the cAMP assay where TC04 appears to 
have increased, or at least has not inhibited, ADM-mediated activity. Cells treated with MK2206, an 
Akt inhibitor, and SC79, an Akt activator, were designed to act as controls. For the MK2206 sample, 
cells were pre-treated with MK2206 and then treated with ADM. If the expected ADM-mediated 
increase in P-FoxO3a was blocked by MK2206 pre-treatment, this would support that the increase in 
P-FoxO3a was Akt-dependent. Cells treated with SC79 were expected to have a significant increase 
in P-FoxO3a, independent of ADM. The densitometric analysis for SC79 and MK2206 samples does 
show that the SC79 sample has a P-FoxO3a ratio of double that of the MK2206 P-FoxO3a ratio, 
suggesting the expected results for these samples have been obtained. However, it is not possible to 
make any definite conclusions due to the extremely low ratios obtained for samples 7-12, of which 
MK2206 and SC79 samples were numbers 11 and 12 respectively. As the samples pre-treated with 
the antagonists TC02, TC10, TC08 and TC12 were numbers 7-10, it has not been possible to 
definitively compare the effects of the antagonists on ADM-mediated activity. However, it does 
appear that all of the antagonists, with the exception of TC04, have P-FoxO3a ratio lower than that 
of the ADM-only treated sample. The low ratios for samples 7-12 are likely to be a result of the faint 
bands obtained for these samples when probed for P-FoxO3a. Whereas the GAPDH bands for the 
same samples and blot were of similar intensities to those of the other blots. A reason for this may 
be that there was a technical issue involving the measurement of the band intensities during 
exposure that did not occur for the other blots, rather than there being a low amount of P-FoxO3a 
protein. However, it is difficult at this stage to come to any conclusive statement. To confirm the 
results obtained for all of the samples, it will be necessary to perform more Western blots 
investigating P-FoxO3a and FoxO3a. Potentially using a FoxO3a antibody that binds to the protein 
away from a phosphorylation site to measure total FoxO3a protein, rather than unphosphorylated 
FoxO3a. Statistical analysis could also then be performed to support the results. More positively, the 
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Western blot has shown that SKNSH cells basally express FoxO3a. Even more so, the results show 
that the cells also express phosphorylated FoxO3a, which appears to be affected by the Akt pathway, 
shown by the less intense band after treatment with the Akt inhibitor MK2206 (lane 11, figure 3.7.). 
This supports that SKNSH cells are an ideal cell line to prove or disprove that ADM-mediates Foxo3a 
phosphorylation.   
The Western blot, a in Figure 3.6, has two quite distinct bands at the molecular mass corresponding 
to the protein of interest, FoxO3a. This makes it difficult to assign the correct FoxO3a band. It may 
be that the different bands are FoxO3a at different stages of phosphorylation, despite the 
immunogen being raised against the non-phosphorylated S253. Phosphorylated proteins may be 
shifted in SDS-PAGE compared to their unphosphorylated counterpart, due to the phosphorylated 
protein having a higher molecular weight. This may have occurred as the antibody is polyclonal and 
so the antibodies will bind to slightly different sites on the protein meaning some may also be able 
to bind the phosphorylated site. Also FoxO3a is phosphorylated at other sites including T32, 
therefore the antibody may bind to FoxO3a where S253 is not phosphorylated but other sites may 
be phosphorylated. Ponceau S staining could be used to stain the PVDF membrane in future Western 
blots to ensure protein transfer has been even. Protein bands are stained red on the membrane 
after Ponceau staining, making it apparent whether protein transfer has been successful and even.  
The black dots visible on the Western blots, particularly a and b of Figure 3.6, may be a result of the 
antibody binding to protein aggregates forming on the blot from the process of rocking the blot in 
the primary antibodies overnight. Although the blot was placed on ice for this stage, the ice 
gradually melted overnight, possibly causing the blot to become unlevelled, and so the coverage of 
the antibody over the blot may have been uneven. The temperature of the blot likely also increased. 
Together this may have promoted protein aggregation. A cold room would be ideal; however, 
rocking the blot in the primary antibody for only one hour at room temperature may also improve 
the quality of the blot.  
Extracting enough protein to perform a Western blot from SK N SH cells was difficult. The ideal total 
amount of protein to load for a Western blot is 20-30 µg per well (according to Abcam’s Western 
blot FAQ – www.abcam.com, accessed 28/07/18). Therefore, the 10 µg loaded for the Westerns in 
section 3.5 was expected to be a little low. Despite this, there are bands, clearly visible (Figures 3.6 
and 3.7), although the bands are too faint to make a conclusive comparison between them. Loading 
a higher amount of protein would potentially make the bands more visible, making them easier to 
analyse and so reach a conclusion on whether there are differences in FoxO3a phosphorylation 
between the different samples. Based on the hypothesis that ADM stimulates FoxO3a 
phosphorylation via the PI3K/Akt pathway, it would be expected that samples treated with ADM 
agonist peptide would have an increased ratio of P-FoxO3a to non-phosphorylated FoxO3a. As a 
positive control, cells treated with the Akt activator, SC79, should also have increased P-FoxO3a. The 
Akt inhibitor, MK2206, should block FoxO3a phosphorylation. The ability of the ADM receptor 
antagonists to inhibit ADM-mediated FoxO3a phosphorylation would give an indication of the 
compounds’ ability to block ADM-receptor activation. Due to the slow growing nature and sensitive 
adherence of SK N SH cells, extracting a higher concentration of protein was not possible by growing 
the cells for treatment in 6 well plates, even when using plates with the Sarstedt Cell+ growth 
surface for sensitively adhering cell lines. Further attempts produced an even lower concentration of 
protein, preventing repeats of the Western blot. Using T25 flasks to culture the cells for treatment 
also did not produce enough protein. However, these T25 flasks did not have the Cell+ growth 
surface, which may explain why the protein yield was not improved compared to the yield when 
using 6 well plates which did have the Cell+ growth surface. The sensitively adhering SK N SH cells 
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are likely to have been lost during washing steps. Growing the cell samples in T25 or perhaps T75 
flasks with the Cell+ growth surface may yield a higher concentration of protein, but this would 
require a lot of space and materials, especially if each sample is performed in triplicate.  
An alternative would be to transfect the cDNA of the ADM receptor genes into cells which do not 
express a functional ADM receptor. This would be particularly advantageous because this method 
would allow the investigation of the effect of the antagonists on each of the two ADM receptors and 
also the CGRP receptor (to check for cross-specificity) separately. For example, cells could be co-
transfected with CALCRL and one of the RAMP genes (RAMP1, RAMP2 or RAMP3); this would lead to 
the expression of either the CGRP, ADM1 or ADM2 receptor, respectively. The cAMP and Western 
blot assays could then be repeated using each of the cell groups, transfected with the different 
receptors, and the effects of the antagonists on each receptor could be directly compared without 
the potential for cross-specificity.  
4.6. Transfection of Cells with ADM Receptor Components 
An attempt was made to co-transfect SH SY5Y cells with CALCRL and RAMP2 (using the method in 
section 2.8), therefore with the aim that the transfected cells would express the ADM1 receptor. The 
SH SY5Y cell line was chosen because it is also a neuronal cell line, actually derived from a subclone 
of SK N SH cells, and so is relevant to MDD. Despite being a subclone of SK N SH, SH SY5Y divide 
more rapidly than SK N SH and also adhere less sensitively. As a result, it was hoped that a higher 
concentration of protein could be extracted from the cells for the Western blot assays. Furthermore, 
although gene expression analysis (Table 3.1) showed that SH SY5Y expresses the receptor genes to 
some degree, cAMP ELISA results (Figure 3.2, graph b) and a brief test using the cAMP-Glo Max assay 
(data not shown) revealed that the cell line does not appear to express a functional ADM receptor. 
More specifically, the cell line does not express a receptor capable of stimulating cAMP synthesis in 
the presence of ADM.  
Western blot analysis of the transfected cells did not appear to result in receptor expression. Protein 
extracts were analysed using antibodies raised against the CLR and RAMP2 proteins and no bands 
were visible. This suggests that the transfection was not successful however, it could also be that 
Western blot conditions have not yet been optimised. With more time, both the transfection and 
Western blot method could be optimised using SH SY5Y and yield better results. If this is not 
successful however, it may be that SH SY5Y do not possess the machinery required to synthesis a 
functional ADM receptor. If so, the transfection could be attempted in HEK 293 cells as this cell line 
is known to be relatively easy to transfect and the ADM receptors have previously been transfected 
in this cell line (Aiyar, Disa, Pullen, & Nambi, 2001). 
 
4.7. Conclusion 
 
In summary, the obstacles addressed in the discussion have made attempting to fulfil the main aims 
of this project more arduous than expected. The most appropriate and available cell line for 
investigating ADM receptor antagonists, in relation to MDD, was found to be SK N SH. The cell line 
expresses the ADM receptors both at the transcriptional level and as a functional receptor, capable 
of stimulating adenylate cyclase upon ADM binding. However, there is the possibility that cross 
specificity of ADM for the CGRP receptor was responsible for the results observed in the cAMP 
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assay. This could be investigated using HUVECs, in a small scale test, as the cells only express the 
ADM1 receptor. The cAMP assay could also be replicated using CGRP as the peptide agonist instead 
of ADM and the results could be compared to see if the effects on cAMP levels are similar for the 
two peptides. This may suggest cross specificity was responsible for the results obtained. Regardless 
of this, SK N SH is still a promising and relevant cell line for the investigation of ADM mediated 
effects in regards to MDD.  
In terms of the most promising antagonists, TC02 appears to be the most effective. The compound 
showed antagonism in both the cAMP assay and the gene expression analysis of CCNB1. These 
assays need to be repeated to back up the results with statistical analysis. The compound did lead to 
cell death in THP-1 cells at concentrations higher than 20 µM. However at lower concentrations, and 
potentially therapeutically relevant concentrations, there was no cell death observed. TC02 also 
appeared to show an ability to reduce the pro-inflammatory marker neopterin. Therefore, in terms 
of a potential therapeutic for MDD, the compound could act in two different ways, by reducing 
inflammation and blocking ADM-mediated activity. Of course, more analysis is needed to confirm 
the effectiveness of the compound.  TC14 was also a promising antagonist in the cAMP assay but 
further experiments are needed to confirm the results were the result of ADM receptor inhibition 
and not CGRP receptor inhibition. The results of the assays have also potentially illuminated the 
possibility of TC04 having agonistic properties in regards to ADM activity and so this should be 
investigated, as this could also have potential therapeutic benefits, in situations where ADM has 
been shown to be protective.  
Western blot experiments have shown that it is possible to identify phosphorylated FoxO3a using 
this technique. As a result, it should be possible to use Western blot to shed light on the effect of 
ADM on P-FoxO3a levels and therefore the effect of ADM on FoxO3a transcriptional activity. If the 
hypothesis is correct that ADM results in FoxO3a phosphorylation, this will be important 
therapeutically and could explain many of the effects seen regarding ADM in disease.  
It is still unclear whether ADM is beneficial or detrimental in the case of MDD. It may be that the 
peptide is increased in MDD patients as a neuroprotective mechanism or that increased ADM 
exacerbates an imbalanced HPA axis, leading to increased stress. In reality, it may be a combination 
of these factors at play. The small molecular antagonist compounds investigated in this project may 
be able to be used in further research, to shed more light on the relationship between ADM and 
MDD, and lead to a more effective treatment for MDD.  
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Appendices 
 
 
A1) Western blot showing bands corresponding to GAPDH for samples 1-6 of the FoxO3a antibody treated 
blot shown as blot a, Figure 3.6. 
 
 
A2) Western blot showing bands corresponding to GAPDH for samples 7-12 of the FoxO3a antibody treated 
blot shown as blot b, Figure 3.6. 
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A3) Western blot showing bands corresponding to GAPDH for samples 1-6 of the P-FoxO3a antibody treated 
blot shown in blot c, Figure 3.7. 
 
 
A4) Western blot showing bands corresponding to GAPDH for samples 7-12 of the P-FoxO3a antibody 
treated blot shown in blot d, Figure 3.7. 
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